The prevention of heparanase expression in endothelial cells injured by high glucose by Han, Ju Ying
  
The Prevention of Heparanase Expression in 
Endothelial Cells Injured by High Glucose 
 
 
 
A Thesis Submitted to the College of 
Graduate Studies and Research 
in Partial Fulfillment of the Requirements for 
the Degree of Masters of Science 
in the Graduate Program of Veterinary Biomedical Sciences 
University of Saskatchewan 
Saskatoon 
 
 
 
Juying Han 
 
 
©Copyright Juying Han, April 2005. All rights reserved. 
 i
 
PERMISSION TO USE 
 
            In presenting this thesis in partial fulfilment of the requirements for a 
Master of Science degree from the University of Saskatchewan, I agree that the 
Libraries of this University may make it freely available for inspection. I further 
agree that permission for copying this thesis in any manner, in whole or in part, 
for scholarly purposes may be granted by Dr. L. Hiebert who supervised my 
thesis work or, in her absence, by the chair of the Graduate Program of 
Veterinary Biomedical Sciences. It is understood that any copying of publication 
or use of this thesis or parts thereof for financial gain shall not be allowed 
without my written permission. It is also understood that due recognition shall be 
given to me and the University of Saskatchewan in any scholarly use which may 
be made of any material in this thesis in whole or in part should be addressed 
to: 
  
Chair of the Graduate Program of Veterinary Biomedical Sciences 
            Western College of Veterinary Medicine 
            University of Saskatchewan 
            52 Campus Drive 
            Saskatoon, SK S7N 5B4 
            Canada 
 
 
 ii
 
PREFACE 
 
            This thesis has been organised as a series of manuscripts that will be 
submitted for publication in scientific journals. Some repetition of introductory 
and methodological material is unavoidable. 
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ABSTRACT 
 
            Vascular complications, in microvessels resulting in nephropathy, 
retinopathy and neuropathy and in macrovessels resulting in atherosclerosis 
caused by hyperglycemia contribute greatly to the morbidity and mortality in 
diabetes mellitus. In the vasculature, the endothelial cells (ECs) are first to be 
damaged by hyperglycemia due to their unique location as the inner lining of all 
vessels. There are several mechanisms involved in endothelial injury or 
dysfunction, however, the degradation of heparan sulfate proteoglycan (HSPG) 
on the cell surface and in the extra cellular matrix (ECM) is considered to be of 
importance. Heparanase is believed to degrade heparan sulfate (HS). Our 
objectives were to determine if heparanase is responsible for endothelial injury 
and dysfunction in diabetes. 
            To determine if hyperglycemia and heparanase cause endothelial injury, 
high concentrations of glucose (30mM), mimicking hyperglycemia and optimal 
doses of heparinase I were used to treat cultured porcine aortic endothelial cells 
(PAECs). Cell injury was measured by determining live cell number and lactate 
dehydrogenase (LDH) release. To determine if heparanase is expressed in high 
glucose treated PAECs, reverse transcriptase polymerase chain reaction (RT-
PCR) was used to amplify heparanase mRNA. In addition, heparanase activity 
was measured by incubating cell lysates with 35S-labelled ECM from cultured 
bovine corneal ECs, where released radioactive HS was analyzed by 
Sepharose gel filtration followed by β-scintillation counting. To help understand 
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the mechanism of high glucose injury, heparanase mRNA and activity were also 
measured in PAECs treated with H2O2 or mannitol to determine if free radical 
injury or osmolarity caused effects similar to high glucose treatment. As well, 
high glucose or heparinase I treated PAECs were also treated with heparin (0.5 
µg/ml) and/or insulin (1 U/ml) and/or basic fibroblast growth factor (bFGF, 1 
ng/ml) to determine if these compounds protected ECs from injury or inhibited 
heparanase expression induced by high glucose. 
            PAECs injured by high glucose or heparinase I (0.3 U/ml in serum free 
medium) showed a significantly decreased live cell number and increased LDH 
release compared to control cells. High glucose or heparinase I treated ECs 
showed an increase in live cell number and decrease in LDH release when 
treated with heparin and/or insulin and bFGF. Heparanase mRNA and activity 
was expressed in PAECs treated with high glucose or H2O2. Heparin and/or 
insulin, but not bFGF prevented heparanase mRNA expression and activity in 
high glucose treated PAECs. Mannitol did not induce the upregulation of 
heparanase mRNA and activity. bFGF showed variable protection in cells 
treated with high glucose or heparinase I when combined with insulin or heparin. 
            From these results we conclude that hyperglycemia is a main cause of 
endothelial injury. Heparanase production induced by hyperglycemia is 
responsible for EC injury and vascular dysfunction likely through the 
degradation of HS, resulting in increased vascular permeability and detachment 
of cells from the basement membrane. The mechanism of heparanase 
upregulation may be related to the formation of reactive oxygen species, but not 
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due to changes in osmolarity. Heparin and/or insulin and bFGF protect cells 
from injury caused by high glucose or heparinase I. Heparin and/or insulin but 
not bFGF inhibit heparanase mRNA upregulation induced by high glucose. This 
study provides new insight into the causes of vascular injury associated with 
diabetes and suggests possible treatments to reduce endothelial injury. 
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1. LITERATURE REVIEW 
 
    1.1. Diabetes 
          1.1.1. Definition of Diabetes 
            Diabetes is defined as a disorder of carbohydrate metabolism. The 
most common form of diabetes is diabetes mellitus (DM) in which there is an 
inability to oxidize carbohydrate due to disturbances in insulin function. 
Insulin is the principal hormone released by pancreatic β-cells that regulates 
uptake of glucose into cells (primarily muscle and fat cells) from the blood. 
Insulin makes it possible for most body tissues to remove glucose from the 
blood for use as fuel, for conversion to other needed molecules, or for 
storage. Insulin is also the principal control signal for conversion of glucose  
to glycogen for storage in liver and muscle cells. If the amount of insulin 
produced is insufficient, if cells respond poorly to the effects of insulin (insulin 
insensitivity or resistance), or if the insulin itself is defective, glucose is not 
handled properly by body cells  nor stored appropriately in the liver and 
muscle. The net effect is persistent high levels of blood glucose, poor protein 
synthesis, and other metabolic derangements. Therefore, diabetes mellitus is 
considered to be a group of diseases characterized by hyperglycemia 
resulting from defects in insulin production, insulin action, or both. Diabetes 
 2
mellitus is typically classified into two main subtypes: type 1 and type 2. Type 
1 diabetes develops when the pancreatic β-cells are destroyed by the bodys 
autoimmune system and can not produce the insulin that regulates blood 
glucose. Type 2 diabetes usually begins as insulin resistance, a disorder in 
which the cells do not use insulin properly. As the need for insulin rises, the 
pancreas gradually loses its ability to produce insulin. Type 1 diabetes 
usually strikes children and young adults and may account for five to ten 
percent of all diagnoses of diabetes. Type 2 diabetes is associated with old 
age, obesity, family history of diabetes, prior history of gestational diabetes, 
impaired glucose tolerance, physical inactivity, and race/ethnicity and may 
account for 90 to 95 percent of all diagnosed cases of diabetes. Type 2 
diabetes is increasely being diagnosed in children and adolescents (National 
Diabetes Statistics 2002). 
 
          1.1.2. Vascular Damage due to Hyperglycemia 
            Hyperglycemia is considered to be one of the most important 
predisposing factors in the development of diabetic complications (Ruderman 
et al., 1992; Lee et al., 1989a; Kamata et al., 1992; Natarajan et al., 1992). 
The evidence linking hyperglycemia and microvascular disease in diabetes 
was obtained in clinical studies. The patients under better glycemic control 
developed fewer eye and/or renal complications (Pirar ， 1977). 
Hyperglycemia causes cell damage which ultimately leads to irreversible 
structural abnormalities characterized by loss of cells and progressive 
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microvascular occlusion in the eye and kidney, and by intimal proliferation 
and occlusion in large vessels (Kohner et al., 1982; Bresnick et al., 1997; 
Steffes et al., 1989; Osterby, 1990).  Hyperglycemia induced microvascular 
hypertension also contributes directly to an increase in vascular permeability, 
and the resultant extravasations of plasma proteins and growth factors, both 
in small and large vessels, may promote irreversible hypertension and vessel 
occlusion. Additional evidence is derived from studies showing that 
hyperglycemia associated with diabetes produce many of the metabolic, 
biochemical, and functional abnormalities seen in the vasculature. At least 
four different mechanisms have been postulated to contribute to these 
abnormalities.  
            The first mechanism which may contribute to diabetic complications is 
an increase in the formation of sorbitol (Tilton et al., 1989; Pugliese et al., 
1990; Bank et al., 1989). In the hyperglycemic state, excess glucose entering 
the polyol pathway can lead to the accumulation of sorbitol by aldose 
reductase coupled with oxidation of reduced nicotinamide-adenine 
dinucleotide phosphate (NADPH) to its oxidized form NADP+. Sorbitol can be 
subsequently converted to fructose by sorbitol dehydrogenase coupled with 
the reduction of oxidized nicotinamide-adenine dinucleotide (NAD+) to the 
reduced form NADH as shown in Figure 1.1. Aldose reductase is ubiquitous 
and therefore polyols accumulate in nearly all tissues of diabetic patients. 
Increased flux through this pathway due to hyperglycemia, increases 
intracellular sorbitol and fructose, increases osmotic pressure, decreases 
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myoinositol concentration, and in combination with glycolysis, alters the 
intracellular redox balance. NADPH is required for nitric oxide (NO) 
regeneration and replenishes the antioxidant glutathione. Thus, increased 
cytosolic NADH/NAD+ ratio decreases NADPH resulting in the formation of 
intracellular reactive oxygen species (ROS), leading to oxidative stress 
(Brownlee, 2001). Certain abnormalities in the microvasculature of diabetic 
rats are prevented by administration of an inhibitor of aldose reductase 
(Beyer-Mears et al., 1986; Craven and DeRubertis, 1989a; Cohen, 1986; 
Robison et al., 1989).   
            The second mechanism is decreased myoinositol-dependent Na/K-   
ATPase as shown in Figure 1.2. Myoinositol is a normal constituent of the 
diet and is also synthesized by many cells (Greene et al., 1987). It plays an 
important role in signal transduction and the synthesis of phosphoinositides 
(PI). Adenosine-mediated hydrolysis of PI leads to the release of a mediator 
that activates Na/K-ATPase and thereby regulates many cell functions. 
Depletion of the intracellular pool of PI caused by a sorbitol pathway-linked 
transport defect and a decrease in its response to adenosine both occur in 
diabetes, which can be prevented by aldose reductase inhibitors (Beyer-
Mears et al., 1986; Robison et al., 1989; Winegrad， 1987).  
            The third mechanism is increased synthesis of diacylglycerol (DAG) 
with the consequent activation of several isoforms of protein kinase C (PKC) 
(Lee et al., 1989a; Craven and DeRubertis 1989b; Williamson et al., 1990). 
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          (© Setter et al. 2003. Figure prepared by Dr. William Light on behalf of Medi 
                Tech Media Ltd) 
 
   
Figure 1. 1.  Polyol Pathway 
Activation of the polyol pathway results in a decrease of reduced NADP+ and 
oxidized NAD+; these are necessary cofactors in redox reactions throughout the 
body. The reduction in these cofactors leads to decreased levels of reduced 
glutathione, NO and myoinositol. 
AGEs: advanced glycation end-products 
NAD: nicotinamide-adenine dinucleotide 
NADH: reduced nicotinamide-adenine dinucleotide 
NADPH: nicotinamide-adenine dinucleotide phosphate 
NADPH+: oxidized nicotinamide-adenine dinucleotide phosphate 
NO: nitric oxide            
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                                                                                    (Clark and Lee, 1995) 
 
         
Figure 1.2. The Aldose Reductase Pathway of Glucose Metabolism 
The aldose reductase pathway is activated by intracellular hyperglycemia, resulting 
in increase sorbitol formation. This, in turn (through an unknown mechanism, 
indicated by the question mark), results in decreased myo-inositol formation and 
ultimately in decreased cellular activity of Na+K+-ATPase. Hyperglycemia also 
directly inhibits ATPase activity. The vertical arrows indicate increases (↑) and 
decreases (↓) in the substances in question. 
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Several studies have shown that hyperglycemia increases DAG 
concentration in several types of vascular cells and tissues and causes an 
activation of PKC, probably by its translocation from cytosol to the membrane 
(Lee et al., 1989a and Lee et al., 1989b). PKC is probably activated by DAG 
synthesized by means of a stepwise acylation of glycerol 3-phosphate 
generated as a by-product of glycolysis. Increased DAG levels and activation 
of PKC have been linked to cell growth, permeability, contractility and 
synthesis of extracellular matrix protein resulting in the abnormal vascular 
function associated with diabetes (Williamson et al., 1990). 
            The fourth mechanism is covalent modification of protein by 
nonenzymatic glycosylation. Nonenzymatic glycosylation has been shown to 
result in qualitative and quantitative changes in extracellular components that 
can affect cell adhesion, growth, and matrix production (Tsilibaru et al., 1988; 
Charonis et al., 1990; Sensi et al., 1989). Many of these effects are mediated 
by advanced glycosylation end-products (AGEs), which form from 1-amino-1-
deoxyketose adducts through a complex series of dehydration, 
rearrangements and redox reactions (Monnier and Cerami， 1983) as 
described in Figure 1.3. Matrix accumulation of AGEs may further accelerate 
diabetic vascular occlusion by blunting the effect of the vasodilatory factor 
NO, which is quenched by AGEs in a dose-dependent fashion (Bucala et al., 
1991).  
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                                                                                       (Clark and Lee, 1995) 
 
 
 
Figure 1.3. Formation of Advanced Glycosylation End Products from Glucose 
The formation of advanced glycosylation end products from glucose occurs through 
the nonenzymatic formation of early glycosylation products (N-glucosylamine) that 
then undergo acid-base catalysis to form Amadori products (1-amino-1-deoxy-
ketose). Advanced glycosylation end products result from the degradation of the 
Amadori products into reactive carbonyl compounds that react with free amino 
groups (R-NH2). The formation of advanced glycosylation end products in vivo is 
retarded by reductase. 
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            Alterations in four such interrelated hyperglycemia-driven pathways 
have been linked to the early microvascular changes associated with 
diabetes in animal and human tissues (Williamson et al., 1988; Walker and 
Viberti， 1991). Hyperglycemia can also contribute directly to microvascular 
occlusion by stimulating extracellular matrix synthesis (Brownlee and Spiro, 
1979; Moran et al., 1991; Mandal et al., 1995). Various abnormalities, such 
as AGEs, PKC and cytokines such as transforming growth factor-beta (TGF-
β), and increased oxidative stress in diabetes contribute to synthesis of 
extracellular matrix proteins, i.e. type IV collagen, laminin and fibronectin. In 
addition, loss of cells may indirectly contribute to further microvascular 
occlusion by stimulating excessive production of extracellular matrix (ECM) 
(McNeil et al., 1989; Okuda et al., 1990; Saito et al., 1988).   
 
          1.1.3. Insulin and Diabetes 
            Insulin, a circulatory hormone produced in response to elevated 
glucose concentration in the blood, regulates the metabolism of glucose. 
Glucose is liberated from dietary carbohydrate such as starch or sucrose by 
hydrolysis within the small intestine, and is then absorbed into the blood. 
Elevated concentrations of glucose in blood stimulate synthesis and release 
of insulin from pancreatic β-cells. Insulin acts on cells throughout the body to 
stimulate uptake, utilization and storage of glucose. Besides its role in 
regulating glucose metabolism, insulin stimulates lipogenesis, diminishes 
lipolysis, and increases amino acid transport into cells. Insulin also 
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modulates transcription, altering cell content of numerous mRNAs. It 
stimulates growth, DNA synthesis, and cell replication, effects that it holds in 
common with insulin-like growth factors (Sowers, 1997; Bornfeldt et al., 
1992). 
            The vasculature is an insulin-responsive tissue. Increased insulin 
concentration and decreased vasculature sensitivity to insulin have been 
identified as independent risk factors for cardiovascular disease in insulin-
resistance syndromes and type 2 diabetes (Despres et al., 1996; Howard et 
al., 1996). The activation of insulin receptors, by insulin binding, results in 
diverse signaling processes that mediate the many actions of insulin in 
vascular cells.  Actions of insulin include the regulation of cell growth, gene 
expression, and protein synthesis. Studies of cultured vascular cells in the 
presence of insulin showed increasing cell mitogenosis, protein synthesis 
and production of matrix proteins. These changes can result in atherogenesis 
through vascular smooth muscle cell (VSMC) hypertrophy and hyperplasia, 
and extracellular matrix protein synthesis (Feener and King, 1997; Howard 
et al., 1996). However, endothelial-derived NO can reduce the progression of 
atherosclerosis through inhibiting proliferation of VSMC and platelet 
adhesiveness (Radomski et al., 1987; Moncada et al., 1988; Mollace et al., 
1991). The ability of insulin to increase production of NO has been shown in 
cultured endothelial cells (ECs) (Zeng and Quon, 1996). NO is an important 
vasodilator and plays a critical role in the regulation of vascular tone and 
blood pressure (Vallance et al., 1989). In contrast, it has been shown that a 
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high dose of insulin increases endothelin-1 (ET-1) levels in cultured ECs 
(Metsarinne et al., 1994; Ferri et al., 1995a; Mandal et al., 2000). Increased 
ET-1 levels are also found in type 2 diabetic subjects in response to 
hyperinsulinemia (Ferri et al., 1995a; 1995b). ET-1 exerts a potent 
vasoconstrictor effect on the vasculature and produces an elevation of 
systemic blood pressure in anesthetized dogs and rats (Yokoawa et al., 
1989; Miller et al., 1989). Some studies showed that hypertensive patients 
have high ET-1 levels in their plasma (Shichiri et al., 1990; Kohno et al., 
1990) and patients with endothelin dependent malignant 
hemangioendothelioma have hypertension induced by an elevated level of 
plasma ET-1 (Yokoawa et al., 1991). The actions of insulin appear to be 
contrary regarding the production of both of NO and ET-1. Reports show the 
ability of insulin to induce vasodilatation is low in insulin resistance and 
diabetes (Steinberg et al., 1996) which could be due to inactivation of NO or 
the inability of ECs to produce NO (Ting et al., 1996). Thus, insulin may have 
antihypertensive and anti-atherogenic actions at an appropriate physiological 
dose or in the non-diabetic state. 
 
          1.1.4   Complications of Diabetes 
            Diabetes mellitus resulting from defects in insulin production, insulin 
action, or both is characterized by hyperglycemia and abnormal lipid and 
protein metabolism. These changes are associated with diabetic 
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complications, especially cardiovascular diseases including microvascular 
disease, macrovascular disease and diabetic cardiomyopathy. 
            Diabetic microvascular disease affects the small vessels such as 
those present in the retina, near nerves and in the microvasculature of the 
kidneys. This systemic disease in diabetes clinically leads to retinopathy and 
glomerular dysfunction, and possibly contributes to neuropathy. A number of 
studies have suggested that hyperglycemia appears to be the central 
initiating factor for all types of diabetic microvascular diseases (Ruderrman et 
al., 1992; Kamata et al., 1992). Some evidence derived from animal studies 
of experimental diabetes with hyperglycemia also showed lesions in the eye 
(Engerman and Kern, 1984) and kidney (Engerman and Kern, 1989; Rasch, 
1981) similar to those in humans. Patients under better glycemic control 
developed fewer eye and/or renal complications in a clinical study (Pirart, 
1977). Non-proliferation diabetic retinopathy is associated with pericyte loss, 
formation of microaneurysms, increased vascular permeability, and capillary 
closure that can lead to areas of non-perfusion and ischemia. The retina 
responds to this hypoxia by increased production of vascular endothelial cell 
growth factor (VEGF), which promotes neovascularisation (Aiello et al., 
1994). In diabetic nephropathy, an increase in both intraglomerular pressure 
and extracellular matrix proteins results in basement membrane thickening, 
mesangial expansion, glomerular hypertrophy and narrowing of the lumen of 
the capillaries (Osterby, 1990). These changes reduce glomerular filtration 
area and function and impede blood flow, and can progress to 
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glomerulosclerosis (Mogensen et al., 1988), resulting in increasing albumin 
filtration rate in the glomerulus in microalbuminuric patients (Deckert et al., 
1989). Diabetic neuropathy refers to a group of diseases that affect the 
peripheral nerves which extend outside the brain and spinal cord and include 
three types: motor, sensory and autonomic nerves. The autonomic nerves, 
not consciously controlled, supply the heart, blood vessel, bladder and 
intestinal tract. Diabetic neuropathy is classified as either peripheral 
(including sensor and motor) or autonomic, with peripheral neuropathy being 
the most common manifestation. Diabetic neuropathy results from both 
chronic and acute elevations in blood glucose. Decreased nerve function by 
acute hyperglycemia and reduced nerve fibers and nerve fiber reproduction 
by chronic hyperglycemia, are believed to occur because of the formation of 
sorbitol and advanced glycosylation end products (Clark and Lee, 1995) 
which cause microangiopathy, causing altered neuronal capillary flow (Koda-
Kimble et al., 1995). 
            Macrovascular complications in diabetes, including coronary artery 
disease, peripheral vascular disease and cerebrovascular disease, is the 
result of an acceleration of atherosclerosis and increased thrombosis. 
Although the relationship between hyperglycemia and macrovascular 
disease in patients with diabetes is complicated by many other factors that 
influence atherogenesis in non-diabetics, an association between 
asymptomatic hyperglycemia and coronary heart disease has been found in 
both middle aged and elderly people (Jarrett et al., 1982; Mykkanen et al., 
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1990). Many factors, some of which may exist in the prediabetic state, 
particular in type 2 diabetes, are involved in the etiology of macrovascular 
disease. Hyperlipidaemia, hypertension, hyperinsulinaemia and decreased 
insulin sensitivity related to the insulin-resistance syndrome have been 
proposed to induce atherogenesis even before the clinical diagnosis of type 2 
diabetes (Haffner et al., 1990). In addition, diabetes is associated with 
coagulopathy and endothelial dysfunction with impaired NO production, 
compounding the effects of hyperglycemia in promoting atherogenesis (Jokl 
and Colwell, 1997). A number of factors, such as hyperinsulinaemia, insulin 
precursors, and tumor necrosis factor-α (TNF-α) are thought to increase 
plasma plasminogen activator inhibitor-1(PAI-1) concentrations. Local 
changes in vascular PAI-1 expression, which is increased in the neointima of 
atherosclerotic lesions, may also have an impact on the fibrinolytic balance in 
injured vessels. High PAI-1 levels inhibit fibrinolysis and facilitate the 
persistence of fibrin, which may damage the endothelium (Lupu et al., 1993). 
Endothelial dysfunction may reduce the antithrombotic properties of the 
endothelium by decreasing the synthesis of prostaglandin I2 (PGI2) and 
diminishing the endothelial protective effects against platelet adhesion (Wu 
and Thiagarajan, 1996). The common features in diabetic vascular disease, 
due to development of chronic hyperglycemia, are exaggerated proliferation 
of endothelium and thickening of the basement membrane (Fischer et al., 
1979; Osterby, 1990; Kefalides, 1981) which result in narrowing of the blood 
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vessel lumen causing thrombosis, ischemia, and ultimately infarction (Colwell 
and Lopes-Virella, 1988).   
            Diabetic cardiomyopathy is characterized by cardiac contractile 
dysfunction and congestive heart failure due to myocellular hypertrophy and 
myocardial fibrosis (Bell, 1995). This induces abnormal left ventricular filling 
suggesting poor compliance or prolongation of left ventricular relaxation. The 
exact cause of this ventricular dysfunction is not known, but several 
mechanisms have been proposed, including (1) metabolic abnormalities of 
glucose transport; (2) increased extracellular matrix in the interstitium of the 
ventricular wall showed by increased type IV collagen and a combination of 
nonenzymatic glycation and enzymatic O-linked glycosylation. This may be 
the result of increased 2 N-acetylglucosaminyl transferase, that is increased 
in diabetic rat hearts (Nishio et al., 1995); (3) abnormalities in fatty-acid 
metabolism and alteration of calcium uptake by the sarcoplasmic reticulum 
leading to cellular calcium overload. These changes can result in stiffer 
ventricular walls and impaired myocyte contractility (Mizushige et al., 2000; 
Tahiliani and McNeill, 1986). In addition, coronary heart disease may make a 
large contribution to heart failure in diabetic cardiomyopathy. 
 
          1.1.5. Morbidity and Mortality of Diabetes 
            Cardiovascular disease is the major burden of diabetes mellitus. Both 
macrovascular and microvascular disease contribute greatly to the morbidity 
and mortality in diabetes (Kassab et al., 2001). Diabetes is associated with 
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accelerated atherosclerotic macrovascular disease affecting arteries that 
supply the heart, brain and lower extremities. As a result, patients with 
diabetes have much higher risk of myocardial infarction, stroke, and limb 
amputation. Up to 80% of deaths in people with type 2 diabetes are attributed 
to cardiovascular disease and stroke (Hanefeld et al., 1996). It is well 
established that chronic hyperglycemia results in microvascular 
complications in diabetes which is the leading cause of renal failure and 
blindness, contributing to more than 33,000 new cases of end-stage renal 
disease (United States Renal Data System, 2002) and more than 24,000 
new cases of vision loss each year in the US (Diabetes 2001 vital statistics). 
According to the statistics of the American Diabetes Association (2002), the 
total economic cost including direct costs (cost of medical care and services) 
and indirect costs (cost of short term and permanent disability and premature 
death) is about 132 billion. 
  
    1.2   Endothelial Dysfunction in Diabetes 
          1.2.1. Function of Endothelium  
            The endothelium is a distributed organ consisting of a monolayer of 
metabolically active cells lining all blood and lymphatic vessels. It plays an 
important role in the structural integrity and normal function of the circulatory 
system. The vascular endothelium has extensive regulatory capacities and 
senses changes in hemodynamic forces and blood borne signals to release a 
number of vasoactive substances which are critical to maintain vascular 
homeostasis. 
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            Endothelium acts as a selective permeability barrier for substances 
including H2O, CO2, ions, small lipid molecules, and plasma proteins for 
exchange between the blood and extravascular tissue, maintaining the 
homeostatic balance between the intra and extra cellular environment. 
           Endothelial cells normally inhibit platelet adhesion and aggregation by 
producing PGI2 and nitric oxide (NO). Endothelial cells limit activation of the 
coagulation cascade by the thrombomodulin-protein C and the heparan 
sulfate-antithrombin III pathway, and regulate fibrinolysis by producing tissue 
plasminogen activator (tPA) and its inhibitor-1 (PAI-1), and thus maintain 
blood fluidity (Borsum, 1991; Pearson, 1991). 
            Endothelium plays a role in metabolism by displaying enzymes 
responsible for a number of important biochemicals reactions including 
angiotensin converting enzyme (ACE) which is an ectoenzyme found on the 
luminal surface of the endothelium. The function of ACE is to convert 
angiotensin I to angiotensin II, a vasopressor (Webb and Cockcroft, 1990). 
            Endothelial cells secrete multiple vasoactive substances critical in the 
regulation of vascular tone as well as a wide array of cytokines and growth 
factors such as transforming growth factor-beta (TGF-β) and angiotensin II. 
Endothelium affects vascular smooth muscle and mensangial cell function by 
producing mediators such as NO and endothelin-1. Endothelin-1 stimulates 
contraction and proliferation of smooth muscle and mesangial cells while NO 
has opposite effects (Cohen and Tesfamariam, 1992; Stehouwer, 1998). 
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          1.2.2. The Concept of Endothelial Dysfunction 
            The vascular endothelium is not a mere barrier between intravascular 
and interstitial compartments, but a widely spread organ, which is 
responsible for the regulation of hemodynamics, angiogenic vascular 
remodeling, and metabolic, synthetic, inflammatory, antithrombogenic, and 
prothrombogenic processes. As any other organ, the vascular endothelium is 
a subject for dysregulation, dysfunction, insufficiency, and failure. Endothelial 
dysfunction describes disturbances in the barrier function of the vascular 
endothelium, impaired antithrombogenic properties; perturbed angiogenic 
capacity; inappropriate regulation of vascular smooth muscle tonicity, 
proliferative capacity, migratory properties; perturbed synthetic functions; and 
prevention of neutrophils and monocytes from diapedesis.      
 
          1.2.3. Endothelial Dysfunction Associated with Hyperglycemia 
            The vascular endothelium is the initial target site of injury in diabetes. 
The proximate causes of endothelial injury are not known but likely include 
hyperglycemia, exporsure to advanced glycosylation end-products, activation 
of protein kinase C, increased expression of TGF-β and vascular endothelial 
growth factor (VEGF), oxidative stress and other components of the insulin 
resistance syndrome which are hyperinsulinaemia, hypertension and 
dyslipidaemia (Stehouwer et al., 1997). These factors probably contribute to 
endothelial dysfunction in human diabetic complications and include the 
following: the endothelium loses its antithrombotic and profibrinolytic nature 
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and may instead acquire prothrombotic and antifibrinolytic properties, a 
transition marked by high plasma levels of thrombomodulin and PAI-1. 
Platelet adhesion and aggregation are no longer inhibited but may actually 
be stimulated by prethrombotic factors released from injured endothelial 
cells, such as Tissue Factor and von Willebrand Factor (vWF) (Stehouwer, 
1998). Endothelium-dependent, nitric oxide-mediated vasodilatation 
decreases and vascular smooth muscle cell contraction is enhanced so 
hypertension ensues (Elliott et al., 1993). One of the most important forms of 
endothelial dysfunction is basement membrane thickening and an increase in 
vascular permeability which may result from loss of heparan sulphate 
proteoglycan (HSPG) (Kanwar et al., 1980). The glomerular filter is 
compromised and an increased albumin filtration rate in the glomerulus is 
observed in microalbuminuric patients (Deckert et al., 1989). 
 
    1.3. Degradation of Heparan Sulfate Proteoglycan (HSPG) 
          1.3.1. Proteoglycans 
            Proteoglycans (PGs) are ubiquitous macromolecules that are 
produced by most eukaryotic cells, and are found predominantly on the cell 
surface, in the ECM and intracellular granules (Kjellen and Lindahl, 1991). 
The structure of these PGs includes a core protein onto which are bound 
numerous sulfate and/or acetylated polysaccharide chain subunits called 
glycosaminoglycans (GAGs). PG structure begins with the core protein which 
may contain a few or many GAG binding sites which are substituted to 
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various degrees with side chain polysaccharides made up of repeating 
hexosamine and hexuronic acid subunits. These can include both acetylated 
and sulfated components organized in patterns which impart localized 
regions of high anionic charge alternating with neutral segments (Choay and 
Petitou, 1986). The relative arrangement of these charged and uncharged 
areas provides the molecule with additional information carrying ability. The 
unique structural features of PGs endow them with properties that may 
influence a wide range of biological processes. Several physically related 
GAGs including heparan sulfate (HS), dermatan sulfate, chondroitin sulfate, 
and hyaluronic acid have been identified in association with cell membranes 
and in the ECM (Hook et al., 1984) and     play a major role in cell-cell and 
cell-protein interaction. 
 
          1.3.2. Heparan Sulfate Proteoglycans  
            HSPGs, found on cell membranes and in the ECM, are prominent 
components of blood vessels. In large vessels, they are concentrated mostly 
in the intima, where endothelial cells lie on their basement membrane (BM), 
and in the inner media which contains ECM including several elastic laminae. 
In capillaries they are found mainly in the subendothelial BM, where they 
support proliferation and migrating ECs and stabilize the structure of the 
capillary wall.The BM contains type IV collagen associated with laminins, 
entactin and HSPGs. HSPGs play an important role in the interaction 
between cell to cell and cell to ECM or BM. 
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            The ECM is a meshwork-like substance found within the extracellular 
space and includes the BM of cells. The ECM not only provides structural 
support to cells and tissues, but also plays important roles in regulating the 
behavior of cells in multicellular organisms. The ECM is composed of a 
complex mixture of proteins and PGs including HSPGs. Almost all of the 
proteins are glycoproteins having short chains of carbohydrate residues 
attached to them. The proteins include a wide variety of collagens, laminins 
abundant in the basal lamina of epithelia, fibronectin binding cells to the 
ECM, and elastins providing flexibility to arteries, lungs, and skin.  
Fibronectin interacting with PGs, fibrin/fibrinogen and collagens are important 
for cell adhesion, growth and migration. The PGs promote adhesion of the 
cell to ECM through binding molecules such as fibronectin and laminin. 
Endothelial cells have been shown to synthesize the constituents of the ECM 
and control vascular permeability to macromolecules by modulating the 
biochemical and biophysical properties of the ECM (Chon et al., 1997; 
Borsum, 1991).  
            HSPGs like syndecans are also on the cell surface, and are believed 
to be the endogenous receptor for circulating growth factors i.e., basic 
fibroblast growth factor (bFGF), TGF-β, VEGF, hepatocyte growth factor 
(HGF) and chemokines that regulate cell proliferation, differentiation and 
migration (Linhardt and Toida, 1997). The ability of the HS side chains to 
interact with enzymes such as coagulation factors, mast cell proteases, 
lipoprotein lipase and cytokines such as  granulocyte macrophage-colony 
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stimulating factor, interferon, interleukins also suggests an involvement in the 
control of normal and pathologic processes, such as wound healing, tumor 
growth and vessel formation (Vlodavsky et al., 1993).  Hence, HSPGs play 
important roles in physiological processes of embryonic development, tissue 
repair, and regulation of blood coagulation, cartilage function and glomerular 
filtration (Kjellen and Lindahl, 1991; Bernfield et al., 1992; Salmivirta and 
Jalkanen, 1995). Several disease conditions such as cardiovascular 
diseases, cancer, inflammation, diabetes and amyloidosis are associated 
with changes in the expression of PGs as well as with structural and 
functional alterations of their GAG components (Rosenberg et al., 1997; 
Iozzo and Cohen, 1993; Jackson, 1997; van der Woude and van Det, 1997). 
 
          1.3.3. A Unique Heparan Sulfate: Heparin 
            Heparin is biosynthesized and stored in the basophilic granules of 
mast cells which are located in connective tissue, near the capillaries and in 
the walls of blood vessels, and is released as a GAG. Heparin is more highly 
sulfated, has high negative charge density and uronic acid is primarily 
iduronic acid versus glucouronic acid in heparan sulfate. Both heparin and 
HS have a high negative charge density, the result of sulfate and carboxylate 
residues present in their structure (Harpel et al., 1996) as described in Figure 
1.4. These negative charges on the luminal surface of endothelium are 
thought to play an important role in controlling vascular permeability by acting 
as a charge barrier to the transvascular movement of the largely anionic 
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plasma protein such as albumin (Hardebo and Kahlstrom, 1985). Exogenous 
heparin is used as an anticoagulant and/or antithrombotic agent to maintain 
blood flow in the vasculature through the binding and activation of 
antithrombin III and other mechanisms (Harpel et al., 1996). Exogenous 
heparin is also capable of ameliorating increased vascular permeability 
caused by various polycationic substances including protamine, poly-L-lysine 
or neutrophil cationic protein (NCP) (Fairman et al., 1987; Peterson et al., 
1987). Heparin is considered as a potent vasodilator that most likely lowers 
elevated blood pressure in hypertensive animal models by interacting with 
vascular endothelial cyclic 3-5- guanosine monophosphate (cGMP) or 
releasing endothelial derived NO (Mandal et al., 1995). NO may 
subsequently suppress ET-1 production by a cGMP-dependent pathway 
(Boulanger and Luscher, 1990) decrease VSMC contractility and increase 
vascular wall refractoriness to other vasoconstrictor substances (Mandal et 
al., 1995). In addition, heparin has antiviral activity, binds to a variety of 
growth factors, inhibits complement activation and regulates angiogenesis 
(Casu, 1985; Lane and Linhardt, 1989). 
            The ability of heparin to protect endothelium has been demonstrated 
by a number of studies: (1) Heparin administered by parenteral and oral 
routes accumulates within endothelium with its concentration hundreds to            
thousands-fold more than in plasma (Hiebert et al., 1993). (2) Heparin 
increases amounts of HS on EC surfaces (Nader et al., 1991). (3) Heparin is  
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                                                                                                         (Garg et al., 2000) 
  
Figure 1.4. Major and variable sequences of original and fully sulfated heparin 
(A) and heparan sulfate (B).  
There are more negative charges in the sequences of fully sulfated versus original 
heparin and heparan sulfates 
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protective of cultured ECs damaged by exposure to free radicals (Hiebert 
and Liu, 1990).(4) Heparin in a time- and dose-dependent manner smoothes 
the endothelial surface and reduces actin and vimentin expression, shown by 
immunofluorescence microscopy (Mandal et al., 1995). (5) Heparin, insulin or 
a combination of insulin and heparin prevented EC intercellular gaps when 
cultured in high concentrations of D-glucose as viewed by scanning electron 
microscopy. In addition high glucose treated cultured VSMCs, showed 
enhanced actin expression which was blunted with addition of either heparin 
or insulin (Mandal et al., 2000).  
 
          1.3.4. Effect of HSPG Degradation 
            Depletion of HS and/or abnormal GAG metabolism appears to be a 
pivotal mechanism for EC dysfunction that is associated with various 
vascular complications of diabetes. The steno hypothesis, first advanced by 
Deckert et al., in 1989, held that a genetic defect in the regulation of heparan 
sulfate produced by endothelial, myomedial, and mesangial cells determines 
the susceptibility of diabetic patients to develop proteinuria and angiopathy 
with its associated cardiovascular risk. Some diabetic patients have a genetic 
trait leading to lower activity of the enzymes response for GAG sulfation 
under hyperglycemic conditions (Gambaro and van der Woude, 2000). 
Studies using biochemical techniques to measure GAG content of kidneys, 
obtained at autopsy, demonstrated that the glomerular basement membrane 
(GBM) of the patients with diabetic nephropathy contained less GAG than the 
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kidneys of nondiabetic control subjects (Parthasarathy and Spiro, 1982; 
Shimomura and Spiro, 1987). Similar changes in HS content in the intima of 
the aortas of patients with diabetes mellitus have been observed (Wasty et 
al., 1993), suggesting that the abnormalities in HS metabolism are not 
necessarily restricted to the kidney. This would explain the association 
between diabetic cardiovascular mortality and nephropathy. Using HSPG 
monoclonal antibody (JM-403), some studies showed that decreased GBM 
staining intensity correlated with the degree of proteinuria in diabetic 
nephropathy (Tamsma et al., 1994) and staining of skin basement membrane 
was also significantly reduced in patients with diabetic nephropathy 
compared to control diabetic patients with long-standing diabetes without 
nephropathy (van der Pijl et al., 1998). Other studies also showed decreased 
serum HS and increased urine GAGs in patient with overt diabetic 
nephropathy (Yokoyama et al., 1999; Perez-Blanco et al., 2000). 
Subcutaneous exogenous heparin significantly reduced proteinuria in patient 
with diabetic nephropathy (Myrup et al., 1995). 
 
          1.3.5. Basic Fibroblast Growth Factor (bFGF) Released by HSPG  
                 Degradation 
            The function of growth factors is to couple cells to their environment     
and provide the cells with plasticity to respond appropriately to external 
changes or to changes in their own state (Sporn and Roberts, 1993). Binding 
of growth factors to cell receptors, can transduce a signal to the cell nucleus. 
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The fibroblast growth factors (FGFs) are a family of cytokines, a group of 
polypeptides characterized by high affinity to heparin and HSPG which affect 
the growth, differentiation, and migration of many cell types (Folkman and 
Klagsbrun, 1987). The affinity of bFGFs for HSPGs limits bFGF diffusion and 
release into the interstitial space (Moscatelli, 1987; Flaumenhaft et al., 1990). 
bFGF molecules probably remain mostly intracellular (Vlodavsky et al., 
1987), but are normally stored in the vascular basement membranes (Baird 
and Ling, 1987) where PGs serve as a reservoir for growth factors. When 
needed for wound healing, including vascular cells damaged by 
hyperglycemia (Folkman and Klagsbrun, 1987), bFGF is released by 
endothelial damage (Muthukrishnan et al., 1991) and mobilized by enzymatic 
hydrolysis from the vascular basement membrane (Baird and Ling, 1987). 
bFGF has high potential for proliferation of capillary endothelial cells in vitro 
and only picomolar quantities can promote angiogenesis in vivo (Broadley et 
al., 1989; Folkman and Klagsbrun, 1987). The biological effects of FGFs are 
exerted through interaction with the FGF receptor (FGFR). The FGFRs are a 
family of transmembrane tyrosine kinases which are activated upon ligand 
binding (Zimmer et al., 1993). Binding of bFGFs to bFGFRs results in 
autophosphorylation of receptors and signaling to the cell (Bellot et al., 
1991). Heparin/HS is a constituent of the FGF/FGFR signaling complex and 
can modulate FGF activity and specificity (Ornitz, 2000). Some enzymes that 
synthesize and degrade HS also affect the function of FGFs. Many studies 
have shown that bFGF can be released from HS in the ECM by enzymes 
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such as heparanase, trypsin or plasmin (Bashkin et al., 1990; Saksela et al., 
1990). Inhibition of heparanase activity can inhibit bFGF release (Ishai-
Michaeli et al., 1990). Heparanases break down HS, remove HS from its 
protein core and also degrade HS into oligosaccharides (Bame, 2001). As 
well, plasmin digests the protein core of HSPG (Giardino et al., 1994) and 
reduces HS production in vascular cells (Kaji et al., 1994). Both heparanases 
and plasmin interfere with binding of HSPG to bFGF/bFGFR forming a 
bFGF/HS /bFGFR complex, and therefore, decrease the stability of bFGF 
and result in loss of bFGF due to lack of HS. This lack of HS can be 
corrected by exogenous heparin (Yayon et al., 1991; Nissen et al., 1999). A 
study of nonenzymatic glycosylation of bFGF showed that the decreased 
activity of bFGF in hyperglycemia (Giardino et al., 1994) could be prevented 
by heparin/HS (Nissen et al., 1999). 
 
    1.4. Heparanase 
          1.4.1. The Properties of Heparanase 
            Heparanase is an endo-β-D-glucuronidase capable of cleaving 
glycosidic bonds of heparan sulfate side chains at a limited number of sites 
with a hydrolase mechanism. The degraded HS fragments are still an 
appreciable size (5-7 KDa) (Vlodavsky and Friedmann, 2001; Freeman and 
Parish, 1998). This suggests substrate specificity of the enzyme recognizing 
a particular and relatively rare HS structure (Bourin and Lindahl, 1993; 
Camejo et al., 1998). Particularly, a 2-O sulfate group on a hexuronic acid 
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residue located two monosaccharide units away from the cleavage site 
appears to be essential for substrate recognition by heparanase (Conrad, 
1998) as shown in Figure 1.5. Among the cell types, including platelets, 
cytotrophoblasts, mast cells, neutrophils, macrophages, and T and B 
lymphocytes, that express heparanase under normal physiological 
conditions, platelets have high levels of heparanase (Freeman and Parish, 
1998; Freeman et al., 1999). In fact, serum heparanase is mainly derived 
from activated platelets (Ihrcke et al., 1998). The content of heparanase in 
the kidney is second to the placenta among various organs. Furthermore, 
heparanase is only rarely expressed either in human ECs or in bovine aortic 
ECs exposed to various physiological activators (Godder et al., 1991; 
Nakajima et al., 1986). ECs are able to bind, internalize, and degrade high-Mr 
heparin, and since HS is similar to heparin, this suggests that ECs contain an 
endoglucosidase that degrades HSPG intracellularly (Barzu et al., 1987; 
Godder et al., 1991).  
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                                                                               (Vlodavsky and Friedmann, 2001) 
 
 
Figure 1.5. Cleavage of HSPG by Heparanase   
Heparanase cleaves HSPGs (arrows) and releases a variety of physiologically and 
pathologically important molecules. Inset shows the heparanase recognition and 
cleavage site. X in sugar unit 4 represents hydrogen or SO3¯. 
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            Recently, partial sequencing of heparanase purified from human 
placenta, platelets, and hepatoma cells led to the cloning of a cDNA and 
gene encoding the heparanase protein (Vlodavsky et al., 1999; Hulett et al., 
1999; Toyoshima and Nakajima, 1999). Heparanase gene is located on 
human chromosome 4q21.3. The heparanase cDNA contains an open 
reading frame of 1629 bp encoding a 61.2 KDa polypeptide of 543 amino 
acids. The mature active 50 KDa enzyme has its N-terminus 157 amino acids 
downstream from the initiation codon (Vlodavsky et al., 1999; Toyoshima and 
Nakajima, 1999; Fairbanks et al., 1999) suggesting post-translational 
processing of the heparanase polypeptide at an unusual cleavage site as 
shown in Figure 1.6. Processing and activation occur during incubation of the 
full-length 65 KDa recombinant enzyme with several normal and transformed 
cells and to a less extent, with their conditioned medium (Vlodavsky et al., 
1999). The heparanase precursor may bind to the cell surface, most likely to 
HS, and is then converted to its highly active 50 KDa form in a process 
accompanied by endocytosis of the processed form. This is demonstrated by 
the observation that heparanase activity is readily obtained after transfection 
of mammalian cells with cDNA encoding the entire heparanase precursor 
(Vlodavsky et al., 1999; Dempsey et al., 2000a).  
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                                                                                                 (Vlodavsky et al., 2001) 
 Figure 1.6.  Scheme of the Human Heparanase Gene and Protein. 
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            Heparanase is also localized to tertiary granules of neutrophils and 
mast cells and is released upon tumor necrosis factor (TNF-α) and calcium 
ionophore treatment (Matzner et al., 1985; Mollinedo et al., 1997; Bashkin et 
al., 1990). Heparanase release by degranulation has been implicated in 
diapedesis and extravasation of a number of immune cells, including 
neutrophils, macrophages, and lymphocytes (Vlodavsky et al., 1992; Bartlett 
et al., 1995; Parish et al., 1998), while heparanase inhibitors exhibited anti-
inflammatory activity (Parish et al., 1998). Cleavage of HS side chains by 
degranulated heparanase during inflammation may facilitate the passage of 
blood borne normal and malignant cells into tissues by altering the 
composition and structural integrity of the subendothelial ECM (Vlodavsky 
and Friedmann, 2001; Vlodavsky et al., 1992; Bartlett et al., 1995). 
Heparanase may facilitate the release of a multitude of HS bound growth 
factors, cytokines and chemokines that would enhance the immune reaction 
or activate the vascular endothelium (Vaday and Lider, 2000; Elkin et al., 
2001). 
 
          1.4.2. Pathogenesis Caused by Heparanase 
            HSPGs play a key role in the self-assembly and integrity of the multi-
molecular architecture of basement membrane and ECMs, hence, their 
cleavage is likely to alter the integrity and functional state of tissue and to 
provide a mechanism by which cells can respond rapidly to changes in the 
extracellular environment. Enzymatic degradation of HS is, therefore, 
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involved in diverse fundamental biological and pathological phenomena 
associated with cell migration, including embryonic morphogenesis, 
angiogenesis, inflammation, neurite outgrowth, tissue repair and cancer 
metastasis (Wight et al., 1992; Bandtlow and Zimmermann, 2000; Nakajima 
et al., 1988; Vlodavsky et al., 1992; Parish et al., 1999). Since HSPGs are 
important constituents of blood vessels and the basement membrane, 
cleavage of HS is expected to facilitate extravasation of blood-borne tumor 
cells, as well as sprouting of angiogenic ECs by modulating growth factor 
activity and bioavailability. Cancer invasion and metastasis involves 
degradation of ECM components, including collagens, laminins, fibronectin 
and HSPGs. The malignant cell is able to accomplish this task through the 
concerted sequential action of enzymes such as matrix metalloproteinases 
(MMPs), serine and cysteine proteases, and endoglucosidases. Expression 
of heparanase is associated with the metastatic potential of tumor cells 
(Vlodavsky et al., 1999; Hulett et al., 1999; Parish et al., 2001; Nakajima et 
al., 1988; Vlodavsky et al., 1994) and increased levels of heparanase have 
been found in sera of animals and human cancer patients bearing metastatic 
tumors (Nakajima et al., 1988). 
 
          1.4.3. Heparanase in Diabetes 
            In the patient with overt diabetic nephropathy, HS and HSPG were 
found to be decreased by using newly developed monoclonal antibodies with 
reactivity to human HS and HSPG core proteins (Tamsma et al., 1994; van 
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den Born et al., 1992; 1993). A decreased intensity of HS staining correlated 
with proteinuria expressed as a function of creatinine clearance (Tamsma et 
al., 1994) suggesting alteration of HSPG side chains relevant in the 
pathogenesis of diabetic nephropathy. The abnormalities in HSPG 
metabolism were also observed in the intima of the aortas of diabetic patients 
suggesting changes in HSPG could occur in both the macro- and micro-
vasculature. Heparanase cleaves HS at specific interchain sites and induces 
loss of the anionic barrier on the luminal surface of endothelium resulting in a 
widespread rise in vascular permeability and vasculopathy. This result was 
determined by observing an increased GBM permeability after perfusion with 
bacterial heparinase (Rosenzweig and Kanwar, 1982).  
            Heparanase activity was found in the urine of some diabetic patients 
associated with poor glycemic control (Katz et al., 2002). Although 
heparanase protein was located in both the glomerular mesangial and 
epithelial cell lysates, there was little or no detectable activity in intact cells 
and their conditioned medium (Katz et al., 2002). This result was confirmed 
by immunohistochemical staining showing the presence of the heparanase 
protein in both the glomeruli and the tubules of normal human and rat kidney 
(Levidiotis et al., 2001).    
 
    1.5. Summary 
            There is evidence from many studies that endothelial dysfunction is 
the predisposing factor that causes diabetic vascular complications due to its 
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unique location and physiological properties in the vasculature. Deckert et 
al., established the steno hypothesis in 1989 which indicated that the 
genetic dysregulation of HS/GAG production was associated with diabetic 
cardiovascular complications. Based on their hypothesis, HSPG degradation 
has received the greatest focus among the several mechanisms of 
endothelial dysfunction in diabetic studies. Evidence from studies of both 
humans and animals demonstrated that the content of HS and HSPG were 
reduced in glomerular and skin basement membrane and in the intima of 
aortas in diabetic patients. HSPG synthesis was also reduced in organs of 
diabetic rats. However, what causes HSPG degradation in the diabetic 
condition is still unknown. Heparanase is believed to break down HS 
resulting in the release of bFGF, enzyme, and plasma proteins (Vlodavsky et 
al., 2001). bFGF then is easily degraded by proteases and loses its mitogen 
activity (Sommer et al., 1989). Degradation of HSPG causes increased 
vascular permeability and damage to the vascular wall due to loss of 
negative charges and detachment of cells from basement membrane. 
            Recently, most studies on heparanase expression are in the field of 
tumor progression and metastasis. The heparanase mRNA and protein are 
preferentially expressed in metastatic cell lines and specimens of human 
breast, colon and liver carcinomas (Vlodavsky et al., 1999). The study of 
heparanase expressed by vascular ECs in vitro and angiogenic blood 
vessels showed that the heparanase protein is only expressed in capillaries 
and small sprouting blood vessels, but not in the endothelium of mature 
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quiescent vessels of the human tumor (Elkin et al., 2001).  In addition, intact 
original human ECs and their lysates rarely express heparanase and 
exposure of ECs to various physiological agents reveal no detectable 
induction of heparanase release. These results suggest that ECs release 
heparanase only when cells are injured or during cell death (Godder et al., 
1991). Heparanase may be synthesized in the endothelial cells under 
harmful stimuli such as hyperglycemia, AGEs, and inflammatory cytokines 
causing a reduction in the anionic sites in GBM and vessels, resulting in 
proteinuria or vascular disease.  
            The studies of heparanase expression in diabetes have been 
restricted to diabetic nephropathy.These studies localized heparanase 
protein both in glomeruli capillaries and tubular epithelium and detected 
heparanase activity in the urine of diabetic patients (Katz et al., 2002). There 
has been no study of heparanase levels in other diabetic cardiovascular 
complications except for nephropathy or in vascular endothelium injured by 
hyperglycemia. Therefore, we hypothesize that hyperglycemia induces 
endothelial injury due to the upregulation of heparanase. HSPG degradation 
caused by increased heparanase activity provides a possible mechanism 
involved in the EC injury. We also hypothesize that heparin and/or insulin 
and/or bFGF inhibit heparanase expression thereby protecting cells from 
hyperglycemic injury at cellular and molecular levels.  
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  2. OBJECTIVES  
 
            The purpose of this study is to determine the effect of medium 
mimicking hyperglycemia (high concentration of D-glucose) on cultured 
porcine aortic endothelial cells (PAECs). Effects of high glucose or 
heparanase on endothelial cell injury will be determined. The ability of insulin 
and/or heparin and/or bFGF to protect ECs from high glucose and 
heparanase injury will also be determined. 
 
       The specific objectives of this study are: 
! To maintain viable PAECs as an in vitro model of human diabetic 
cardiovascular complications 
! To determine if PAECs are injured by high glucose (30 mM) and 
if this injury is prevented by heparin and/or insulin and/or bFGF 
! To determine if heparanase mRNA is expressed in high glucose 
treated PAECs and if this expression is inhibited by heparin and/or insulin or 
by bFGF 
! To determine if heparanase activity is expressed in high glucose 
treated PAECs and if this activity is prevented by heparin and/or insulin 
! To determine if free radicals (H2O2) induce heparanase 
production  
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! To determine if an increase in osmolarity (30 mM mannitol) 
causes heparanase production. 
! To determine if heparanase causes PAEC injury and if this injury 
is prevented by heparin and/or insulin and/or bFGF 
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3. Protection of Porcine Aortic Endothelial Cell Injury  
    from High Glucose by Insulin, Heparin and bFGF 
 
    3.1. Introduction 
            Diabetes mellitus (DM) is a group of diseases characterized by 
hyperglycemia and associated with vascular complications including 
microangiopathy and macroangiopathy (Ruderman et al., 1992; Lee et al., 
1989a). The hallmarks of microangiopathy are diabetic retinopathy and 
nephropathy leading to blindness and renal failure (Ruderrman et al., 1992; 
Kamata et al., 1992; Aiello et al., 1994; Pirart, 1977). Macroangiopathy in 
diabetes, includes coronary artery disease, peripheral vascular disease, 
cerebrovascular disease, and is the result of an acceleration of 
atherosclerosis and increased thrombosis, thus increasing the risk of 
myocardial infarction, stroke and ischaemia (Mogensen et al., 1988; Jarrett et 
al., 1982; Mykkanen et al., 1990). 
            The endothelium, a simple monolayer of metabolically active cells 
lining the inner surface of all blood and lymphatic vessels, plays an important 
role in the structural integrity and normal function of the circulatory system. 
The endothelium synthesizes and releases many vasoactive substances 
including endothelial derived nitric oxide (NO), prostaglandin I2 (PGI2), tissue 
plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), 
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angiotensin II, angiotension-converting enzyme (ACE), endothelin-1 (ET-1), 
transforming growth factor- beta (TGF-β), etc. to maintain endothelial 
integrity, regulate the vascular tone and to maintain blood fluidity and 
homeostasis (Webb and Cockcroft, 1990; Cohen and Tesfamariam, 1992; 
Stehouwer, 1998).  
            Since the initial injury in diabetes mellitus takes place in the blood 
vessel, the endothelial cells (ECs) are considered to be the first cells targeted 
by hyperglycemia. Under hyperglycemic conditions, the normal function of 
ECs is perturbed due to loss of its antithrombotic and profibrinolytic nature, 
increase in platelet adhesion and aggregation, and decrease in NO mediated 
vasodilation (Stehouwer, 1998; Elliott et al., 1993). A considerable body of 
evidence in human studies indicates that endothelial dysfunction is closely 
associated with the development of retinopathy, nephropathy and 
atherosclerosis in diabetes mellitus (Stehouwer and Schaper, 1996; 
Stehouwer et al., 1997). 
            Hyperglycemia is almost certainly the predisposing factor in the 
development of diabetic complications. Patients under better glycemic control 
developed fewer eye and/or renal complications (Pirart, 1977). 
Hyperglycemia causes endothelial dysfunction through several mechanisms 
including the accumulation of sorbitol, alterations in the cellular redox state, 
changes in the regulation of protein kinase C (PKC), decrease in Na/K-
ATPase and formation of nonenzymatic glycosylation of proteins (Tilton et 
al., 1989; Pugliese et al., 1990; Bank et al., 1989; Greene et al., 1987; Lee et 
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al., 1989a; Craven and DeRubertis, 1989b; Williamson et al., 1990; Tsilibaru 
et al., 1988; Charonis et al., 1990; Sensi et al., 1989). Hyperglycemia also 
causes cell damage contributing to cell loss and progressive microvascular 
occlusions in the eye and kidney, as well as intimal proliferation and 
occlusion in the macrovasculature (Kohner et al., 1982; Bresnick et al., 1997; 
Steffes et al., 1989; Osterby, 1990). 
  Although there are two broad categories of ECs, namely macro 
(large vessel) ECs and micro (small vessel) ECs, based on their site of origin 
with their own different properties, both express the pathological features 
associated with diabetic complications. These features are exaggerated 
proliferation of ECs and thickening of the basement membrane (BM) (Fischer 
et al., 1979; Kefalides, 1981; Osterby, 1990).  Endothelial oxidative stress 
represents another common pathological mechanism for atherosclerosis in 
diabetes (Ceriello et al., 1996). 
            Among the pathogenesis of diabetic endothelial dysfunction, 
depletion of heparan sulfate (HS) and/or abnormal glycosaminoglycan (GAG) 
metabolism appear to be a pivotal mechanism that is associated with various 
vascular complications. Heparan sulfate proteoglycan (HSPG) and HS were 
decreased in glomerular basement membrane (GBM) in patients with overt 
diabetic complications which correlated with the degree of proteinuria 
(Tamsma et al., 1994; van den Born et al., 1992; 1993). Similar changes in 
HS content in the intima of aortas of diabetic patients have been observed 
(Wasty et al., 1993). The skin basement membrane in patients with diabetic 
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nephropathy was also significantly reduced compared to diabetic patients 
without nephropathy and a reduced 35S-labeled HSPG synthesis was 
observed in aorta, liver and intestinal epithelium of experimentally diabetic 
rats (Brown et al., 1982; Kjellen et al., 1983; Levy et al., 1984). This evidence 
demonstrates that changes in HS metabolism could occur in any tissue or 
organ in addition to the kidney in the diabetic condition, suggesting the link 
between HS abnormalities and vascular complications both in large and 
small vessels in diabetes. 
            HSPGs are synthesized by vascular ECs and incorporated into the 
cell surface and subendothelial basement membrane and extracellular matrix 
(ECM) (Muir, 1997; Simionescu and Simionescu, 1993; Hook, 1984). HSPGs 
with their negative charged sulfate and carboxylate residues, create a 
charge barrier, thought to play an important role in controlling vascular 
permeability to the anionic plasma proteins (Hardebo and Kahlstrom, 1985). 
HSPGs interacting with fibronectin, laminin and collagen in ECM are 
responsible for maintaining the integrity of the vessel wall (Kraemer, 1971; 
Hedman et al., 1982). HSPGs act as a reservoir for HS related growth factors 
such as bFGF. Binding of bFGF to HS ensures the normal function of bFGF 
for cell growth and proliferation. Degradation of HSPGs could cause ECs to 
lose their negative charge and disassemble from the ECM leading to an 
increase in vascular permeability, damage to the vessel wall, and changes in 
growth factor activity. 
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Heparanase is an endo-β-D-glucuronidase that cleaves HS at specific 
interchain sites. Under normal physiological conditions, heparanase is 
expressed in platelets, cytotrophoblasts, mast cells, neutrophils, 
macrophages, and placenta (Freeman and Parish, 1998; Freeman et al., 
1999). Degradation of HS by heparanase results in the release of growth 
factors, enzymes and plasma proteins (Vlodavsky and Friedmann, 2001). 
Under pathological conditions, heparanase activity is found in cancer cells 
with metastatic potential and in activated cells of the immune system (Parish 
et al., 2001; Vlodavsky et al., 1999). Heparanase activity was also found in 
the urine of some diabetic patients and heparanase protein was expressed in 
both the glomerular mesangial and epithelial cell lysates, but not in intact 
cells (Katz et al., 2002). It is possible that EC injury by hyperglycemia is due 
to HSPG degradation by upregulation of heparanase. Thus we wished to 
determine if heparanase was upregulated in high glucose treated ECs.  
            Insulin, heparin and a combination of insulin and heparin prevented 
the intercellular gaps of ECs cultured in high glucose (Mandal et al., 2000). 
Evidence from several previous studies has shown that insulin has the ability 
to increase production of NO in cultured ECs to ensure the normal function of 
blood vessels (Zeng and Quon, 1996; Vallance et al., 1989). As well, heparin 
can accumulate in ECs at a greater concentration than in plasma, can 
increase amounts of HS on the EC surface, and can prevent ECs from free 
radical injury (Hiebert et al., 1993; Nader et al., 1991; Hiebert and Liu, 1990). 
Therefore, we postulated that insulin and/or heparin would protect ECs from 
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high glucose injury synergistically through protecting HSPG from degradation 
by inhibiting heparanase production. 
 bFGF has a high affinity for heparin and HSPGs which is required for 
bFGF activity but also limits bFGF diffusion and release into interstitial 
spaces (Moscatelli, 1987; Flaumenhafl et al., 1990). The high affinity of bFGF 
for heparin and HSPG together with the high potential of bFGF for 
proliferation in cultured capillary ECs (Broadley et al., 1989) may prevent 
HSPG degradation. Previous studies have shown that both heparanase and 
plasmin decreased the stability of bFGF/HS/bFGFR complex resulting in loss 
of bFGF due to HS degradation which was corrected by exogenous heparin 
(Yayon et al., 1991; Nissen et al., 1999). As well the decreased activity of 
bFGF in hyperglycemia due to nonezymatic glycosylation was prevented by 
heparin/HS (Giardino et al., 1994; Nissen et al., 1999). Thus, the stabilization 
of bFGF/HS/bFGFR complex, by supplying heparin and bFGF, may protect 
ECs from injury by high glucose or heparanase. 
 The purpose of our study was to determine if hyperglycemic 
concentrations of D-glucose induce cultured EC injury and if heparanase had 
a similar damaging effect on ECs. As well, we wished to determine if 
supplementation of insulin and/or heparin and/or bFGF could protect cells 
from high glucose or heparanase injury demonstrating their protective effect 
on HSPG degradation of ECs. 
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    3.2. Methods and Materials 
          Isolation of Porcine Aortic Endothelial Cells (PAECs) 
            Porcine aortic endothelial cells (PAECs) were cultured according to 
the method of Gotlieb and Spector (1981). Primary cultures of PAECs were 
obtained directly from the porcine aorta. The aorta segment was cut and 
suspended in calcium- and magnesium-free Dulbeccos phosphate-buffered 
saline (CMF-DPBS) three times, while connective tissue was trimmed away 
from the outside of the aorta and small pieces were cut off of each end. One 
end of the aorta was clamped with two hemostats (ensuring no leakage from 
bottom or branch points). The lumen of the aorta was rinsed with DPBS three 
times and then filled with collagenase solution (Type IV, Sigma, St. Louis, 
MO, USA; 1 mg/ml in CMF-DPBS at 37ûC). Collagenase solution was 
removed after approximately 6 minutes and the endothelial surface of the 
aorta was gently rinsed with M199 (GibcoBRL, Life Technologies, Inc., Grand 
Island, NY, USA) containing 5% fetal bovine serum (FBS, GibcoBRL, Life 
Technologies, Inc.,), 50 µg/ml penicillin and 10 µg/ml streptomycin. The 
medium in the aorta was removed and plated onto 60 mm tissue culture 
dishes. The volume was made up to 2 ml medium following plating. Cells 
were incubated at 37ûC with 5% CO2 / 95% air in a humidified environment.  
Endothelial cells were identified by their morphological appearance of a 
monolayer of cobblestone-like flattened cells and the presence of vWF in 
initial cultures. Non-endothelial-like cells, such as smooth muscle cells and 
fibroblasts were destroyed by mechanical suction before the first passage.  
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          PAEC Culture Conditions 
            To subculture the cells, confluent 60 mm dishes of PAECs were 
washed twice with sterile CMF-DPBS, followed by exposure to a sterile 
0.025% trypsin solution for two or three minutes at room temperature. To 
ensure all cells were suspended, the medium with cells was pipetted back 
and forth in the dishes.  The cells were then resuspended in 6 ml of culture 
medium and seeded onto three 60 mm dishes (2 ml/dish). The cells become 
confluent in 4 to 5 days. The cells were continually subcultured, with or 
without a freezing step for storage, up to passage 3 and were then seeded 
onto 35 mm dishes (usually one 60 mm dish was passed to six 35 mm 
dishes) for use in experiments which become confluent in 3 to 4 days. 
          For freezing cells, PAECs were washed twice with CMF-DPBS, were 
harvested by 0.025% trypsin, and resuspended in culture medium. The cell 
suspension was centrifuged at 1,500 rpm for five minutes, and then the cells 
were resuspended in the freezing medium containing 60% of FBS, 30% 
culture medium and 10% dimethyl sulfoxide (DMSO) (V/V). After cooling for 1 
hr at 4ûC, cells were frozen at - 70ûC. When required, frozen cells were 
thawed at room temperature and seeded onto 60 mm dishes with fresh 
culture medium. The cell medium was changed after the cells attached to the 
bottom of the dishes, about two hours later. 
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          Reagents Used in PAEC Treatment 
            D-glucose, heparin and insulin were first prepared as a stock solution 
in CMF-DPBS. The concentration of stock solution for glucose (D-Glucose, 
BDH Inc. Toronto, Canada) was 540 mg/ml (3M), bovine lung heparin (151 
USP U/mg Upjohn Pharmaceuticals, Kalamazoo, MI, USA) was 0.1 mg/ml, 
insulin (Humulin® N) was 100 U/ml. Heparinase I and bFGF were prepared in 
M199 without serum. The concentration of stock solutions for heparinase I 
(SIGMA) was 10 U/ml and 1 U/ml and for bFGF (SIGMA) was 0.1 ng/µl. 
 
          Addition of High Glucose, Heparin, Insulin and bFGF to PAEC 
          Medium   
            Cell medium was changed just prior to addition of reagents. For 
addition of high glucose, 10 µl of 540 mg/ml (3 M) glucose stock solution was 
added to 1 ml medium to give a final concentration of 5.4 mg/ml (30 mM). For 
heparin addition, 5 µl of 0.1 mg/ml heparin stock solution was added to 1 ml 
medium to give a final concentration 0.5 µg/ml. For insulin addition, 10 µl of 
100 U/ml insulin stock solution was added to 1 ml medium to give a final 
concentration of 1 U/ml. For bFGF addition, 10 µl of 0.1 ng/µl of bFGF was 
added to medium to give a final concentration of 1 ng/ml. Cell medium was 
changed and glucose, insulin, heparin and bFGF were added fresh every 
other day for seven days. Cells were harvested 48 hrs after the last addition 
of reagents. 
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          Determination of Culture Conditions and Optimal Doses of   
          Heparinase I Damage to PAECs 
            In order to determine the culture conditions and damaging doses of 
heparinase I in PAECs, three experiments were done. Concentration of 
heparinase I, 0.01 U/ml, 0.05 U/ml, 0.1 U/ml, 0.3 U/ml and 0.5 U/ml in 
medium, was produced by adding 10 µl of 1 U/ml of heparinase I and 5µl, 10 
µl, 30 µl and 50 µl of 10 U/ml of heparinase I to 1 ml cell medium 
respectively. Cells were cultured either in medium with serum for six or ten 
days, where cell medium was changed and fresh heparinase I was added 
every other day; or in serum free medium for two days by adding heparinase 
I once.   
 
          Addition of Heparinase I, Heparin, Insulin and bFGF to PAEC   
          Medium 
            Cell medium was changed. For heparinase I addition, 30 µl of 10 
U/ml of heparinase I was added to 1 ml cell medium first to give the final 
concentration of 0.3 U/ml. Then heparin, insulin or bFGF was added to 
medium as described above. Fresh reagents were added once. Cells were 
harvested after culture in medium without serum for two days. 
 
          Assessment of Cell Injury 
            Trypan blue exclusion: Number of viable cells was determined by 
using trypan blue dye. Trypan blue is an exclusion dye for distinguishing 
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viable cells in suspension. Live cells excluding dye are not stained blue, 
while dead cells incorporating the dye are stained blue. To assess the extent 
of cell injury, cell medium was removed and 100 µl was saved in a 
microcentrifuge tube for LDH determination. The cells were washed with 
CMF-DPBS, and then detached using 0.5 ml of 0.025% trypsin for 2-3 
minutes and then cells were suspended in I ml of culture medium. An aliquot 
of 100 µl of the cell suspension was mixed with 10 µl of 0.4% of trypan blue 
solution (SIGMA) for 2-3 minutes. The stained cell suspension was counted 
in a hemocytometer chamber with the light microscope. The number of live 
cells and dead cells (those taking up trypan blue) were counted and 
calculated in the dish. The number of live cells in experimental cultures was 
expressed as percent of cells in control cultures for each experiment. 
 
            Lactate dehydrogenase (LDH) assay: LDH released from damaged 
cells to medium is another indicator of cell injury. The Sigma Diagnostic Kit 
No. 228-UV was used to measure the LDH content in the medium. A 50 µl of 
sample was added to 500 µl of reagent and LDH was quantified 
spectrophotometrically by the rate of change in absorbance at 340 nm at 
room temperature. The increased absorbance at 340 nm is the result of 
reduction of NAD to reduced NADH as LDH catalyzes the conversion of 
lactate to pyruvate as shown by the following reactions:  
                                       LDH 
            Lactate +NAD                       Pyruvate +NADH + H+ 
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Therefore, the rate of NADH production is directly proportional to the LDH 
activity in the sample. 
 
          Statistical Analysis   
             All data were expressed as mean +/- standard error (SE) from three 
dishes per group. A one way ANOVA was used to determine significant 
differences between groups. Values of P<0.05 were considered to be 
statistically significant. 
 
    3. 3. Results 
        Isolation of Porcine Aortic Endothelial Cells 
            The protocol to isolate PAECs developed according to Gotlieb and 
Spector (1981) was successful and easy to perform. Although cells were 
contaminated by some unwanted cells, such as fibroblasts and SMVCs, 
these cells were easily distinguished by their morphological appearance from 
the cobblestone-like endothelial cells in the primary culture. These cells were 
then removed by mechanical suction when cells were passed the first time. 
Purified endothelial cells were obtained following several passages. 
    
          PAECs Injured by High Glucose were Protected by a Combination 
          of Heparin and Insulin 
            In order to determine if high glucose induces PAEC injury and if injury 
is prevented by a combination of heparin and insulin, PAECs passage 4 were 
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exposed to high glucose (30 mM), insulin (1 U/ml), heparin (0.5 µg/ml) and 
glucose plus heparin plus insulin for seven days. Cell medium was changed 
and fresh reagents were added every other day. Cells were counted and 
LDH release in medium was determined 48 hrs after the last addition of 
reagents. 
            As shown in Figure 3.1, PAECs treated with glucose showed a 
significant decrease in live cell number and a significant increase in LDH 
release compared to control cells, suggesting that glucose injures PAECs. 
There were no significant changes in live cell number and LDH release in 
PAECs treated with heparin alone and a significantly increased live cell 
number in PAECs treated with insulin alone compared to control cells 
suggesting heparin had no effect on cells and insulin promoted cell 
proliferation. The combination of heparin and insulin in the presence of high 
glucose significantly increased live cell number and decreased LDH release 
compared to cells injured by high glucose alone suggesting their protective 
effect on cells injured by high glucose. 
 
          The Protective Effect of Insulin and/or Heparin on PAECs Injured  
          by High Glucose 
            In order to determine if insulin and /or heparin protect PAECs from 
high glucose injury, PAECs passage 4  were treated with high glucose (30 
mM), glucose plus insulin (1 U/ml), glucose plus heparin (0.5 µg/ml) and  
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Figure 3.1. PAECs Injured by High Glucose were Protected by a Combination 
of Heparin and Insulin 
 
PAECs passage 4 were exposed to glucose (30 mM), insulin (1 U/ml), heparin          
(0.5 µg/ml) and glucose plus heparin plus insulin for seven days. Cell medium was    
changed and fresh reagents were added every other day. Cells were counted and 
LDH release in medium was determined 48 hrs after last addition of reagents. 
Results are expressed as mean+/-SE of three dishes per group. For live cell number, 
significantly different than a, control; b, glucose; c, glucose+heparin+insulin (P 
<0.001). For LDH release, significantly different than any other group (*P<0.01) 
(one way ANOVA). 
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glucose plus insulin plus heparin for seven days. Cell medium was changed 
and fresh reagents were added every other day. Cells were counted and 
LDH release to medium was determined 48 hrs after the last addition of 
reagents. 
          As shown in Figure 3.2, a trend towards a decrease in live cell number 
and a significant increase in LDH release were seen in PAECs treated with 
high glucose showing glucose injury to cells. As well, a significant increase in 
live cell number and decrease in LDH release was seen in PAECs treated 
with high glucose and a combination of insulin and heparin suggesting the 
protective effect of a combination of insulin and heparin on glucose injured 
cells, similar to results shown in Figure 3.1. There was a significant increase 
in live cell number and a corresponding significant decrease in LDH release 
when insulin was added to high glucose injured cells suggesting the 
protective effect of insulin on glucose injured cells. PAECs treated with 
glucose plus heparin showed no significant increase in live cell number, but a 
significant decrease in LDH release compared to high glucose alone.  
 
        Insulin and/or Heparin Protected PAECs from Glucose Injury  
        When bFGF is Present in Cell Medium 
            In order to determine if insulin and/or heparin protected PAECs from 
glucose injury when bFGF is present in cell medium, PAECs passage 4 were 
treated with high glucose (30 mM), glucose plus bFGF (1 ng/ml), glucose plus 
bFGF plus insulin (1U/ml), glucose plus bFGF plus heparin (0.5 µg/ml) and  
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Figure 3.2. The Protective Effect of Insulin and/or Heparin on PAECs Injured 
by High Glucose 
 
PAECs passage 4 were treated with glucose (30 mM), glucose plus insulin (1 U/ml), 
glucose plus heparin (0.5 µg/ml) and glucose plus insulin plus heparin for seven 
days. Cell medium was changed and fresh reagents were added every day. Cells were 
counted and LDH release to medium was determined 48 hrs after the last addition of 
reagents. Results are expressed as mean+/-SE of three dishes per group. For live cell 
% of control, significantly different than a, control; b, glucose; c, glucose + heparin 
(P<0.01). For LDH release, significantly different than a, control; b, glucose; c, 
glucose+heparin; d, glucose+ insulin (P<0.001) (one way ANOVA). 
 
 
Li
ve
 C
el
l %
 o
f C
on
tr
ol
20
40
60
80
100
120
140
160
180
200
C- control
G-glucose (30 mM)
G+H- glucose+heparin (0.5 ug/ml)
G+I- glucose+insulin (1 U/ml)
G+H+I- glucose+heparin+insulin
C G G+H G+I G+H+I
LD
H
 R
el
ea
se
 %
 o
f C
on
tr
ol
0
50
100
150
200
250
b
abc
b
abcd
b
a
 56
glucose plus bFGF plus insulin plus heparin for seven days. Cell medium 
was changed and fresh reagents were added every other day. Cells were 
counted and medium LDH was determined 48 hrs after the last addition of 
reagents. 
            As shown in Figure 3.3, a significant decrease in live cell number and 
increase in LDH release was shown in high glucose treated cells versus 
control cells showing high glucose damages cells. The combination of insulin 
and heparin had a protective effect on high glucose injured cells when bFGF 
was present in cell medium as shown by a significant increase in live cell 
number and decrease in LDH release in cells treated with glucose plus bFGF 
plus insulin plus heparin versus high glucose alone. In addition, a significant 
increase in live cell number and decrease in LDH release was shown in cells 
treated with high glucose plus insulin plus bFGF versus glucose alone 
suggesting the protective effect of insulin on glucose injured cells when 
bFGF is present in cell medium. Heparin with bFGF and bFGF alone added 
to cells injured by high glucose showed a significant increase in live cell 
number versus high glucose treatment alone. Although LDH release was less 
in high glucose plus heparin plus bFGF and high glucose plus bFGF treated 
groups versus the high glucose alone treated group, this difference did not 
reach significance. The combination of insulin plus bFGF, and insulin plus 
heparin plus bFGF was more protective than bFGF and bFGF plus heparin 
on high glucose treated cultures, when numbers of live cells were  
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Figure 3.3. Insulin and/or Heparin Protected PAECs from High Glucose Injury 
when bFGF was Present in Cell Medium 
 
Passage 4 PAECs were treated with glucose (30 mM), glucose plus bFGF (1 ng/ml), 
glucose plus bFGF plus insulin (1U/ml), glucose plus bFGF plus heparin (0.5ug/ml) 
and glucose plus bFGF plus insulin plus heparin for seven days. Cell medium was 
changed and fresh reagents were added every other day. Cells were counted and 
medium LDH was determined 48 hrs after the last addition of reagents. Results are 
expressed as mean+/-SE of three dishes per group. For live cell % of control, 
significantly different than a, control; b, glucose; c, glucose+bFGF; d, 
glucose+bFGF+heparin (P<0.01). For LDH release, a, significantly different than a, 
control; b, glucose; c, glucose+bFGF; d, glucose+bFGF+heparin (P<0.05) (one way 
ANOVA). 
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considered. The combination of insulin plus heparin plus bFGF was more 
protective than bFGF plus heparin when LDH was considered. 
 
 
          Determination of the Optimal Damaging Dose of Heparinase I  
A. Heparinase I dose response in PAECs cultured in M199 with 
serum when treated for six days    
            PAECs were exposed to different doses of heparinase I (0.01 U/ml, 
0.05 U/ml, 0.1 U/ml and 0.3 U/ml) for six days. Cell medium was changed 
and fresh heparinase I was added to cell medium every other day. Cells were 
counted and LDH release to medium was determined 24 hrs after the last 
addition of heparinase I.   
            As shown in Figure 3.4, there are no significant differences in live cell 
number and LDH release in control cultures compared to those treated with 
different doses of heparinase I, suggesting that heparinase I did not injure 
cells grown and treated in M199 with serum. 
 
B. Heparinase I dose response in PAECs cultured in M199 with 
serum when treated for 10 days   
            PAECs were exposed to different doses of heparinase I (0.01 U/ml, 
0.05 U/ml, 0.1 U/ml and 0.3 U/ml) for ten days. Cell medium was changed 
and fresh heparinase I was added to cell medium every other day. Cells were 
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Figure 3.4. Heparinase I Dose Response Shown in PAECs Cultured in M199 
with Serum when Treated for Six Days 
 
PAECs were exposed to different doses of heparinase I (0.01 U/ml, 0.05 U/ml, 0.1 
U/ml and 0.3 U/ml) for six days. Cell medium was changed and fresh heparinase I 
was added to cell medium every other day. Cells were counted and LDH release to 
medium was determined 24 hrs after the last addition of heparinase I. Results are 
expressed as mean+/-SE of three dishes per group(one way ANOVA). 
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counted and LDH release to medium was determined 24 hrs after the last 
addition of heparinase I. 
            As shown in Figure 3.5, there are no significant differences in live cell 
number between groups treated with different doses of heparinase I when 
these groups were compared to control. Although there is a significantly 
greater LDH release with increased doses of heparinase I (0.1 U/ml and 0.3 
U/ml) compared to lower doses of heparinase I (0.05 U/ml), LDH release in 
control cells is significantly greater than lower doses of heparinase I (0.01 
U/mand 0.05 U/ml). LDH release increase in the control group compared to 
some heparinase I treated groups suggests that cells were damaged with 
longer incubation time. Therefore, heparinase I had no damaging effect on 
PAECs exposed to M199 with serum even after 10 days of treatment. 
 
C. Heparinase I dose response in PAECs cultured in serum free  
                 M199    
            PAECs were exposed to different doses of heparinase I (0.05 U/ml, 
0.1 U/ml, 0.3 U/ml and 0.5 U/ml) for 48 hrs in serum free M199. Heparinase I 
was added to cell medium once. Cells were counted and LDH release to 
medium was determined. 
            As shown in Figure 3.6, PAECs treated with different doses of 
heparinase I showed a significant decrease in cell viability and significant 
increase in LDH release compared to the control group suggesting cells were  
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Figure 3.5. Heparinase I Dose Response Shown in PAECs Cultured in M199 
with Serum when Treated for Ten Days 
 
PAECs were exposed to different doses of heparinase I (0.01 U/ml, 0.05 U/ml, 0.1 
U/ml and 0.3 U/ml) for ten days. Cell medium was changed and fresh heparinase I 
was added to cell medium every other day. Cells were counted and LDH release to 
medium was determined 24 hrs after the last addition of heparinase I. Results are 
expressed as mean+/-SE of three dishes per group. There were no significant changes 
in live cell number between groups. For LDH release, a significantly different than  
control; b, significantly different than heparinase I (0.01 U/ml); (P<0.05) (one way 
ANOVA). 
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   Figure 3.6. Heparinase I Dose Response Shown in PAECs Cultured in Serum   
   Free M199 
 
PAECs were exposed to different doses of heparinase I (0.05 U/ml, 0.1 U/ml, 0.3 
U/ml and 0.5 U/ml) for 48 hrs. Heparinase I was added to cell medium once. Cells 
were counted and LDH release to medium was determined. Results are expressed as 
mean+/-SE of three dishes per group. For cell viability, significantly different than a, 
control; b, heparinase I (0.05 U/ml) (P<0.05). For LDH release, a, significantly 
different than control (*P<0.05). For live cell number, no significant difference 
between these groups (one way ANOVA). 
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injured by heparinase I when cells were exposed in serum free M199. 
Furthermore, there is some indication that cell injury was dose dependent 
since there was a significant decrease in cell viability, with heparinase I 0.5 
U/ml compared to 0.05 U/ml.  
            Based on these three experiments we chose the doses of 0.3 U/ml 
heparinase I under serum free media conditions for the following 
experiments. 
           
          Heparinase I Induced PAEC Injury was Prevented by Insulin  
        and/or Heparin 
            In order to determine heparinase I induced PAEC injury was 
prevented by insulin and/or heparin, PAECs passage 4 were treated with 
heparinase I (0.3 U/ml) and/or insulin (1 U/ml) and/or heparin (0.5 µg/ml) for 
48 hrs in serum free M199. Insulin and/or heparin were added immediately 
after heparinase I addition. All reagents were only added once. 
            As shown in Figure 3.7, PAECs were injured by heparinase I as 
shown by a significant decrease in live cell number and increase in LDH 
release compared to control cells. As well insulin and heparin protected cells 
from heparinase I injury as shown by a significant increase in live cell number 
and decrease in LDH release compared to the heparinase I treated cells. 
Furthermore, the combination of insulin and heparin had additional protection 
on cells injured by heparinase I shown by a significant increase in live cell 
number and the lowest LDH release compared to all other groups. 
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Figure 3.7. Heparinase I Induced PAECs Injury was Prevented by Insulin 
and/or Heparin  
 
Passage 4 PAECs were treated with heparinase I (0.3 U/ml) and/or insulin (1 U/ml) 
and/or heparin (0.5 µg/ml) for 48 hrs in serum free medium 199, then cells were 
counted and media LDH was determined. Insulin and/or heparin were added 
immediately after heparinase I addition. All reagents were only added once. Results 
are expressed as mean+/-SE of three dishes per group. For live cell % of control, 
significantly different than a, control; b, heparinase I; c, heparinase I+heparin; d, 
heparinase I+insulin (P<0.001). For LDH release, heparinase group is significantly 
different than any other group (*P<0.005) (One way ANOVA). 
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          The Protective Effect of Insulin and/or Heparin on PAECs Injured 
          by Heparinase I When bFGF is Present in Cell Medium 
            In order to determine the protective effect of insulin and/or heparin on 
PAECs injure by heparinase I when bFGF is present in cell medium, PAECs 
passage 4 were treated with heparinase I (0.3 U/ml), heparinase I plus bFGF 
(1 ng/ml), heparinase I plus insulin (1 U/ml) plus bFGF, heparinase I plus 
heparin (0.5 µg/ml) plus bFGF and heparinase I plus insulin plus heparin plus 
bFGF for 48 hrs in serum free M199. Insulin, heparin and bFGF were added 
immediately after heparinase I addition. 
            As shown in Figure 3.8, PAECs treated with heparinase I showed a 
significant decrease in live cell number and increase in LDH release 
suggesting cells were injured by heparinase I. bFGF alone prevented LDH 
release in heparinase I treated cells, but had no effect on live cell number. 
Insulin and/or heparin and/or bFGF had a protective effect on cells injured by 
heparinase I shown by a significant increase in live cell number and 
decrease in LDH release in cultures treated with bFGF plus insulin, bFGF 
plus heparin and bFGF plus insulin plus heparin alone with heparinase I 
versus heparinase I alone. Furthermore, bFGF plus insulin plus heparin had 
a further protective effect on cells injured by heparinase I when live cell 
number but not LDH release was considered. 
 
 
 
 66
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. The Protective Effect of Insulin and/or Heparin on PAECs Injured 
by Heparinase I when bFGF was Present in Cell Medium 
 
Passage 4 PAECs were treated with heparinase I (0.3 U/ml), heparinase I plus bFGF 
(1 ng/ml), heparinase I plus insulin (1 U/ml) plus bFGF, heparinase I plus heparin 
(0.5 ug/ml) plus bFGF and heparinase I plus insulin plus heparin plus bFGF for 48 
hrs in serum free medium 199, after 48 hrs cells were counted and media LDH was 
determined. Insulin, heparin and bFGF were added immediately after heparinase I 
addition. Results are expressed as mean+/-SE of three culture dishes per group. For 
live cell % of control, significantly different than a, control ; b, heparinase I; c, 
heparinase I+bFGF (P<0.001). For LDH release, heparinase I treated group is 
significantly different than any other group (*P<0.05) (one way ANOVA). 
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    3.4. Discussion 
            Vascular complications are the main causes of morbidity and 
mortality in diabetes mellitus. Endothelial cells (ECs) play many pivotal roles 
in the regulation of vascular tone and integrity, as well as in the maintenance 
of blood fluidity and homeostasis. Since the ECs are considered to be the 
first cells injured by hyperglycemia, endothelial damage is a contributing 
factor in the etiology of vascular complications of diabetes mellitus. Several 
mechanisms of hyperglycemia induced damage of ECs have been 
considered including: increased polyol pathway flux leading to redox state or 
increased oxidative stress, changes in the regulation of protein kinase C 
activated by DAG synthesis, decreased Na/K-ATPase activity and formation 
of nonenzymatic glycosylation of proteins. However, degradation of HSPG on 
the cell surface or in the ECM may play an important role in endothelial injury 
leading to diabetic vascular complications. Heparanase break down of HS 
chains in specific sites may be responsible for the degradation of HSPG 
contributing to endothelial injury. 
            Porcine aortic endothelial cells (PAECs) were used as an in vitro 
model to study human cardiovascular disease associated with endothelial 
injury since there is a similarity between human and porcine tissue (Lee, 
1986). PAEC culture methods have been well established in our laboratory 
for many years. Although endothelial cells can be divided into two categories, 
micro and macro, based on their original site and properties, both categories 
present the same pathological features in diabetic complications. In this 
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study, using ECs from the porcine aorta (macro vessel) exposed to high 
glucose may represent both categories of ECs injured by hyperglycemia in 
vivo. PAECs injured by high glucose showed by decreased numbers of live 
cells and increased LDH release in this study could be thought of as a 
common indicator of EC injury associated with diabetic vascular 
complications. These results agree with previous observations of ECs grown 
under hyperglycemic conditions showing decreased proliferation and 
fibrinolytic potential and increased programmed cell death (Lorenzi, 1992; 
Baumgartner-Parzer et al., 1995). The present result further confirms that 
hyperglycemia causes cell damage and loss of cells that is the initial step 
leading to irreversible structural abnormalities, followed by progressive 
microvascular occlusion in the eye and kidney as well as intimal proliferation 
in large vessels (Kohner et al., 1982; Bresnick et al., 1997; Steffes et al., 
1989; Osterby, 1990). Normal ECs can be induced to become diabetic-like 
cells when cultured in medium with high glucose (30 mM) for ten to twelve 
days (Cagliero et al., 1991a; 1991b), a longer period compared to the seven 
day treatment in our study. The diabetic-like cells however increased their 
proliferation significantly which was demonstrated by culturing diabetic-like 
ECs obtained from umbilical cords of pregnant diabetic women in vitro (Sank 
et al., 1994). PAECs treated with high glucose for seven days in the present 
study may still remain at a normal stage of cell proliferation where cell injury 
was shown by reduced live cell number accompanied by decreased cell 
proliferation. Some variation exists in the response of endothelial cells to high 
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glucose conditions. This variation in cell conditions, includs the use of fresh 
versus frozen cells, variation between animal sources, subtle differences in 
medium, CO2 levels, humidity, and other  unidentified factors. 
          Occlusion in the vasculature could also be the consequence of EC 
injury resulting in alterations in normal physiological properties and release of 
various vasoactive substances. Many studies showed that injured ECs lose 
their antithrombotic and antifibrinolytic nature resulting in decreased 
production of endothelial derived NO and increased ET-1 levels causing 
hypertension and narrowing of the blood vessel; and released growth factors 
and cytokines such as vascular endothelial cell growth factor (VEGF), bFGF 
and TGF-β promoting cell proliferation and synthesis of ECM. All the defects 
occurring during EC injury would result in thrombosis, atherosclerosis, tissue 
ischemia and ultimately vascular infarction. 
          Heparanase activity is involved in diverse fundamental biological and 
pathological processes such as embryonic morphogenesis, angiogenesis, 
inflammation, tissue repair and cancer metastasis. Heparanase is also 
expressed in the kidney and urine of diabetic patients (Katz et al., 2002). 
Since heparanase cleaves HSPG, a component of the EC surface and ECM, 
it may damage ECs and the vessel wall. In order to determine if heparanase 
damages ECs, PAECs were also treated with heparinase I alone to see if 
heparinase I causes EC injury similar to high glucose.  
          Several heparanases have been purified and characterized from 
platelets, placenta, and Chinese Hamster Ovary (CHO) cells named CTAP-III 
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(connective tissue activating peptide III), Hpa I, Hpa II and CHO cell 
heparanases (Karen, 2001). The commercially available heparinase I was 
chosen for the treatment of PAECs. Heparinase I, from Flacobacterium 
heparinum (Cytophagia heparinia), is believed to cleave the specific 
glycosidic linkage in oligosaccharide substrates (Desai et al., 1993). 
Heparinase I did not cause PAEC injury when cells were cultured in M199 
with serum for six to ten days, but showed a dose effect in cells cultured in 
serum-free medium for two days. These findings suggest that heparanase 
exerts its functional activity only under certain conditions. A recently 
discovered cell surface protein, HS/heparin-interacting protein (HIP), was 
involved in preventing heparanase access to its substrate HS by competing 
with the same binding recognition site as in the HS chain (Liu et al, 1997; 
Marchett et al., 1997). This could explain our observations that heparanase 
was active in serum free medium but not in medium with serum, because 
serum may contain HIP. The studies with purified Hpa I heparanase showed 
that at physiological pH the enzyme binds to ECM or cell surface HSPG but 
is inactive. Heparanase activity is optimal between pH 5.0 and 6.5, with 
maximal activity at pH 5.5 to 5.8, and has much less activity above pH 7.0 
(Gilat et al., 1995; Ihrcke et al., 1998). It has been proposed that the pH is 
lowered at sites of inflammation or matrix damage which is favorable for 
heparanase activity (Gilat et al., 1995; Ihrcke et al., 1998; Dempsey et al., 
2000b). Our findings showing cell injury with both high glucose and 
heparinase I treatment suggest that high glucose induces upregulation of 
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heparanase and heparanase breaks down HS causing cell injury. Metabolic 
effect induced by growth in 30 mM glucose may lower the medium pH 
(medium color become yellow). The lower pH stimulates the activation of 
heparanase causing HSPG degradation resulting in endothelial injury. These 
results further confirm that the loss of HS may play an important role in 
diabetic vascular complications. 
          Depletion and metabolic abnormalities of HS and HSPG have been 
found in the kidney, skin and intima of the aortas of diabetic patients with 
nephropathy (Tamsma et al., 1994; van den Born et al., 1992; 1993; Wasty 
et al., 1993). Exogenous heparin significantly reduced proteinuria, the first 
clinical finding in diabetic nephropathy (Tamsma et al., 1996). Heparin 
promotes anticoagulant, antioxidant and barrier properties of blood vessels, 
prevents the formation of occlusive vascular thrombi， protects against 
proteolytic or oxidative damage, and lowers the blood pressure (Harpel et al., 
1996; Fairman et al., 1987; Peterson et al., 1987; Hiebert and Liu, 1990; 
Mandal et al., 1995). Based on the similarity in their basic chemical structure, 
heparin and HS possess common physiological, biological and pathological 
features in the vasculature. Previous studies showed that heparin corrected 
the balance between vascular collagen synthesis and degradation by acting 
on synthesis rather than on degradation (Caenazzo et al., 1997). Heparin 
modifies the synthesis and the structure of HSPG. The ECs possess the 
machinery required for the sulfation of the carbohydrate moiety of a wide 
array of glycoproteins (Colburn and Buonassisi, 1982; Colburn et al., 1987). 
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Therefore, supplementation of cultured ECs exposed to high glucose or 
heparinase I with heparin may protect cells from injury by inhibiting the 
degradation of HS or promoting HS synthesis. Our results showed that 
addition of heparin to ECs treated with heparinase I increased live cell 
number and decreased LDH release significantly compared to cells treated 
with heparinase I alone suggesting that heparin has the ability to prevent cell 
injury by heparanase. Even though the live cell number did not increase 
significantly in cells treated with high glucose and heparin compared to high 
glucose alone, a significant decrease in LDH release and live cell number 
close to control levels also indicate the potential protection of heparin on cells 
injured by high glucose. Taken together, these results may provide evidence 
of the linkage between hyperglycemia and induction of heparanase in 
diabetic complications. Our results are also supported by the observed 
reduction in albumin excretion rate after heparin treatment in diabetic 
patients and animals (Tamsma et al., 1996; Gambaro et al., 1992).  
          HS and heparin have high affinity for bFGF and play a role in the 
formation of the bFGF/bFGFR complex that affects the growth, differentiation 
and migration of many cell types (Folkman and Klagsbrun, 1989). Thus, the 
synthesis and degradation of HSPG is associated with bFGF function which 
is protected by HS synthesis and perturbed by its degradation. Our results 
showed a significant increase in live cell number, but not a significant 
decease in LDH release both in cells treated with glucose plus bFGF and 
glucose plus bFGF plus heparin when compared to glucose alone showing 
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some protective effects of bFGF and/or heparin on high glucose injured cells. 
However, the live cell number in control cells is significantly greater than high 
glucose plus bFGF indicating bFGF alone cannot protect cells from glucose 
injury completely. Since hyperglycemia produces many metabolic, 
biochemical, and functional abnormalities through several cellular pathways, 
the normal function of bFGF may be affected by its interaction with abnormal 
metabolites. Previous studies showed that in hyperglycemia, nonenzymatic 
glycosylation of bFGF decreased bFGF activity (Giardino et al., 1994) to 
some degree and could explain our observations here. Moreover, our 
present results in ECs treated with heparinase I and bFGF and/or heparin 
provide further evidence on the variability of the protective effect of bFGF 
and/or heparin on EC injury under different circumstances. Under conditions 
of serum free medium and without high glucose, cell injury by heparinase I is 
likely due only to the degradation of HSPG. The protection by bFGF of cells 
injured by heparinase I, showed by a significantly decreased LDH release but 
no change in cell number, shows the protective potential of bFGF on cells 
injured by heparinase I.  This protective ability of bFGF is consistent with that 
seen in ECs treated with high glucose and bFGF. When heparin was added 
to ECs treated with heparinase I and bFGF, live cell number increased and 
LDH release decreased significantly compared to heparinase I treatment 
alone. This result suggests that bFGF and heparin bind together to prevent 
HSPG from degradation by heparinase I, which occurs without additional 
interacting factors normally existing in the serum or induced by high glucose.  
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Taken together these findings in ECs treated with heparinase I and heparin, 
cause us to speculate that heparin may exert its protective effect on ECs 
injured by heparanase in two steps: the first, heparin increases synthesis of 
HS on the EC; the second, the newly synthesized HS with exogenous bFGF 
and heparin in cell medium form the complex of bFGF/HS or heparin/ bFGFR 
which is the fundamental structure necessary for bFGF to play its 
physiological role in cell growth, differentiation, proliferation through signal 
transduction. These results suggest that heparin and bFGF work together to 
protect cells from heparanase injury. 
          Insulin not only stimulates cells to take up and utilize glucose to 
regulate blood glucose concentrations, but also promotes DNA synthesis and 
cell growth and replication. The latter effect was supported in this study when 
ECs treated with insulin alone significantly increased live cell number 
compared to controls. The protection by insulin of cells exposed to high 
glucose or heparinase I was shown in all treatment combinations in this study 
including insulin alone, insulin plus heparin, insulin plus bFGF and insulin 
plus heparin plus bFGF. The mechanism by which insulin protects ECs from 
high glucose injury is not entirely understood. Besides its function in 
regulating blood glucose and increasing cell proliferation, insulin can 
increase production of NO in cultured ECs (Zeng and Quon, 1996). NO is a 
most potent endogenous vasodilator and regulates vascular tone and blood 
pressure in vivo (Vallance et al., 1989) and prevents atherosclerosis by 
reducing oxygen consumption (Shen et al., 1994). Endothelial cells grown 
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under hyperglycemic conditions decreased their ability to produce NO due to 
a gene defect in regulation of nitric oxide synthase (NOS) (Chakravarthy et 
al., 1998). The combination of insulin, heparin and bFGF should exert more 
powerful protection on cells injured by high glucose or heparinase I. This is 
based on the intrinsic functions and antioxidative activity of insulin together 
with the multi protective effect of heparin and bFGF on injured cells 
discussed previously.  Indeed, our present studies agreed with this 
speculation and showed that the combination of these three compounds was 
more effective than any other treatment and significantly increased live cell 
number and decreased LDH release compared to high glucose or 
heparinase I alone, heparin plus bFGF, insulin plus bFGF and bFGF alone. 
          In summary, our present studies demonstrate that either high glucose 
or heparinase I cause EC injury, but heparinase I damages ECs under 
limited conditions i.e. in serum free medium. It is therefore confirmed that the 
mechanism of EC injury by high glucose is a complicated process during 
which cells produce a variety of metabolic abnormalities, and the induction of 
heparanase may be one of them. The protective effect of heparin and bFGF 
alone or in combination varied depending on whether cells were exposed to 
high glucose or heparinase I indicating the limited damage induced by 
heparinase I and the complexity of glucose-induced cell injury. The cells 
injured by heparinase I further confirmed that the degradation of HSPG on 
cell surface or possibly the ECM contributes to the vasculopathy associated 
with EC injury that is consistent with previous observations, both in vivo and 
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in vitro, of diabetic vascular complications. Our findings are the first to show 
the protective effects of heparin and/or insulin and/or bFGF on cells injured 
by high glucose or heparinase I. However, interestingly we found that bFGF 
functions differently in the presence of heparin or insulin in cell medium when 
cells were treated with high glucose or heparinase I. The protective effect of 
bFGF plus heparin on ECs damaged by heparinase I is more prominent than 
when ECs were damaged by high glucose. However, bFGF plus insulin 
showed consistent protective effects in cells treated with heparinase I or high 
glucose suggesting that there must be a different interaction between bFGF 
and insulin compared to bFGF and HS or heparin. Regardless of the 
interaction between heparin, insulin and bFGF, this study demonstrated that 
these three compounds in combination protect cells from high glucose or 
heparanase injury.  
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4. Heparanase Upregulation in High Glucose Treated   
  Porcine Aortic Endothelial Cells is Prevented by Insulin   
  and Heparin 
 
    4.1. Introduction 
            Microangiopathy and macroangiopathy, the complications of diabetes 
mellitus, are characterized by development of microvascular pathology in the 
retina and renal glomerulus as well as pathological changes typical of arterial 
disease in macrovasculature (Deckert et al., 1996; Gall et al., 1995; 
Stehouwer and Schaper, 1996). The endothelial cells lining all vessels 
appear to be the initial target in vascular damage by hyperglycemia. This 
endothelial injury is characterized by alteration in anticoagulant and 
profibrinolytic activity (Stehouwer, 1998), a decrease in nitric oxide-mediated 
vasodilation (Elliott et al., 1993), formation of advanced glycosylation end-
products (Kirstein et al., 1990) and exaggerated proliferation of endothelial 
cells and thickening of the basement membrane (Fischer et al., 1979, 
Kefalides, 1981). These abnormalities not only result in vasoconstriction and 
narrowing of the blood vessel lumen, tissue ischemia, and eventually 
infarction, but also contribute directly to an increase in vascular permeability 
(Cowell and Lopes-Virella, 1988; Perejda, 1987).  
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            Heparan sulfate (HS) is a glycosaminoglycan (GAG) that is 
associated with the cell membrane, basement membrane and extracellular 
matrix (ECM) (Kjellen and Lindahl, 1991). Depletion of HS and/or alteration in 
GAG metabolism may be a major mechanism of endothelial injury (Kanwar et 
al., 1980; Deckert et al., 1989). Previous studies showed that diabetic 
patients with a genetic defect in sulfotransferase, an enzyme required for 
GAG sulfation and needed for the regulation of endothelial HS production, 
were more likely to develop proteinuria and angiopathy (Gambaro and van 
der Woude, 2000). Other studies also showed decreased serum HS and 
increased urine GAGs in patients with overt diabetic nephropathy (Perlmutter 
et al., 1989, Shimomura and Spiro, 1982). The highly negatively charged HS, 
due to sulfate and carboxylate residues in its structure, controls the vascular 
permeability by acting as a charge barrier to the largely anionic plasma 
proteins (Hardebo and Kahlstrom, 1985). Although loss of HS is a major 
cause of endothelial injury in angiopathy induced by hyperglycemia, the 
cause of HS degradation is still unknown.  
            Heparanase, an endoglucuronidase, breaks down HS. It is involved in 
fundamental biological phenomena and pathological processes, such as 
inflammation, angiogenesis, autoimmunity and cancer metastasis (Vlodavsky 
and Friedmann, 2001). It is normally found in cytotrophoblasts, platelets, 
mast cells, neutrophils, macrophages, T and B lymphocytes and lymphoma 
(Vlodavsky et al., 1992). Heparanase may be induced by hyperglycemia and 
contribute to EC dysfunction by degradation of HS.  Heparanase activity was 
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found in the urine and heparanase protein was expressed in renal glomerular 
cells of some diabetic patients (Katz et al., 2002). 
            Evidence from previous studies showed that insulin and/or heparin 
prevented the formation of intercellular gaps of endothelial cells cultured in 
high glucose medium (Mandal et al., 2000). This suggests that insulin and/or 
heparin may play a role in protection of endothelial cells from high glucose 
injury by preventing heparanase upregulation. bFGF has high potential to 
increase proliferation of capillary endothelial cells in vitro, has high affinity for 
heparin or HSPG (Broadley et al., 1989) and may inhibit HSPG degradation 
and protect cells from injury. Thus, our objectives were to determine if 
heparanase was upregulated in endothelial cells exposed to high glucose 
and if heparin and/or insulin and/or bFGF protect cells from injury by 
suppressing heparanase expression.  
 
    4.2. Experimental Procedures 
          Endothelial Cell Cultures 
            Porcine aortic endothelial cells (PAECs) were cultured according to 
the method of Gotlieb and Spector (1981). Primary cultures of PAECs were 
obtained directly from the porcine aorta. The aorta segment was cut and 
washed three times in Ca2+-Mg2+-free Dulbeccos phosphate-buffered saline 
(CMF-DPBS) while connective tissue was trimmed from the outside of the 
aorta. The aorta was held in an upright position by clamping one end of the 
aorta with hemostats. The lumen of the aorta was rinsed three times with 
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CMF-DPBS and then filled with collagenase solution (Type IV, SIGMA, St. 
Louis, MO, USA; 1 mg/ml in CMF-DPBS) for six minutes. After removing the 
collagenase solution, the lumen was gently rinsed with M199 (GibcoBRL, Life 
Technologies, Inc., Grand Island, NY, USA) containing 5% fetal bovine 
serum (FBS, GibcoBRL, Life Technologies, Inc), 50 µg/ml penicillin and 10 
µg/ml streptomycin. The medium in the aorta was removed and plated onto 
60 mm tissue culture dishes which were incubated at 37°C with 5% CO2/95% 
air in a humidified environment. PAECs were identified by their morphological 
appearance consisting of a monolayer of cobblestone-like flattened cells, and 
the presence of von Willebrand factor (vWF) in initial cultures. Non-
endothelial-like cells, such as smooth muscle cells and fibroblasts were 
destroyed by mechanical suction before the first passage. In order to pass 
cells, confluent cultures were washed twice with sterile CMF-DPBS and cells 
were removed from the dish by addition of trypsin solution (0.025% with 
EDTA in CMF-DPBS) for two or three minutes at room temperature. The 
cells were resuspended in culture medium and transferred to 60 mm dishes 
for further passage. The cells were transferred to 35 mm dishes at passage 
four for experiments, except when initial cultures were used.  
  
          Reagents  
            Glucose, heparin, insulin, hydrogen peroxide and mannitol were first 
prepared as a stock solution in CMF-DPBS. Concentration of stock solutions 
for glucose (D-Glucose, BDH Inc. Toronto, Canada) was 3M (540 mg/ml), 
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bovine lung heparin (151 USP U/mg Upjohn Pharmaceuticals, Kalamazoo, 
MI, USA) was 0.1 mg/ml, insulin (Humulin® N) was 100 U/ml, hydrogen 
peroxide (H2O2, SIGMA) was 10 mM and mannitol (SIGMA) was 600 mM. 
bFGF (SIGMA) was prepared as a stock solution of 1 ng/µl, and then diluted 
to 0.1 ng/µl in M199 without serum. 
 
          Treatment of Cultured Cells 
            Cultured PAECs passage 4, in 35 mm dishes were treated with high 
glucose, glucose plus heparin, glucose plus insulin and glucose plus heparin 
plus insulin as well as glucose plus bFGF. For glucose addition, 10 µl of 3 M 
(540 mg/ml) glucose stock solution was added to 1 ml culture medium to give 
the final concentration of 30 mM (5.4 mg/ml). For heparin addition, 5 µl of 0.1 
mg/ml heparin was added to 1 ml medium with glucose to give the final 
concentration 0.5 µg/ml. For insulin addition, 10 µl of 100 U/ml insulin was 
added to 1 ml medium with glucose to give a final concentration of 1 U/ml. 
The cells were also treated with glucose plus heparin plus insulin at 
concentrations used when added alone. For bFGF addition, 10 µl of 0.1 ng/µl 
or 1 ng/µl of bFGF was added to 1 ml cell medium with glucose to give a final 
concentration of 1 ng/ml or 10 ng/ml. Medium was changed and glucose, 
insulin, heparin and bFGF were added fresh every other day for seven days. 
Cells were also treated with 30 mM mannitol where 50 µl of 600 mM mannitol 
stock solution was added to 1 ml medium to give a final concentration of 30 
mM. Medium was changed every other day for seven days with fresh 
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mannitol addition. For addition of H2O2, 10 µl of 10 mM H2O2 was added to 1 
ml medium to give a final concentration of 0.1 mM for 24 hrs. Control 
passage four PAECs were also studied as well as initial confluent and non-
confluent cultures. 
 
          Collection of Control Porcine Tissue 
            Samples of liver, aortic smooth muscle and kidney were collected 
from newly slaughtered healthy, untreated pigs. The 50 mg samples were 
stored in RNA stabilization reagent (QIAGEN, RN LaterTM, Mississauga, ON, 
Canada) at room temperature for three or four days. 
 
          Detection of Heparanase mRNA 
            In order to isolate RNA from cells with different treatment and porcine 
tissue, fresh cells in the dish and tissue from the RNA stabilization reagent 
were washed three times in ice cold CMF-DPBS. Then, total RNA was 
isolated according to the manufacturer procedures using RNeasy® Mini Kit 
(QIAGEN). The concentration of RNA was determined by ultraviolet 
absorption at 260 nm using a spectrophotometer (Cary 100 Bio UV-Visible). 
All RNA samples had spectrophotometric ratio of absorbances between 1.7-
2.0 at the wavelengths OD260 and OD280 indicating pure RNA isolates. The 
RNA was visualized on a 1% formaldehyde agarose gel. Then 1 µg of total 
RNA was used to perform Reverse Transcriptase-Polymerase Chain 
Reaction (RT-PCR) using the kit of SupersCriptTM One-Step RT-PCR with 
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Platinum® Taq (InVitrogen. Gibco. Life Technologies. Burlington, ON, 
Canada) and primers specific for rat heparanase gene. The specific primers 
Hep 458 5-CAAGAACAGCACCTACTCA-3 and Hep 1055 5-CACATAAAG 
CCAGCTGCA-3 were designed using Gene Fisher Program to amplify a 597 
bp DNA fragment. The primers were designed to span intron regions in order 
to prevent the amplification of contaminating genomic DNA. As well, the 
internal standard house keeping gene, β-actin, amplified by using sense 
primer 5-GGACTTCGAGACGGAGATGG-3 and anti-sense primer 5-GCAC 
CGTGTTGGCGTAGAGG-3 for each RNA sample was expressed as a 233 
bp cDNA. The RT-PCR profile initially consisted of a cDNA synthesis step of 
30 minutes at 50°C followed by 5 minutes at 94°C to inactive the reverse 
transcriptase and activate the taq polymerase. The RT-PCR conditions were 
an initial denaturation at 94°C for 2 min, and 30 cycles of denaturation at 
94°C for 1 min, annealing at 50°C for 1 min, and extension at 72°C for 2 min. 
The RT-PCR products (10 µl) were run on a 1.5% agarose gel to distinguish 
the 597 bp cDNA fragment of heparanase gene and 233 bp cDNA for β-actin 
which were visualized by agarose gel within 0.5-1 µg/ml of ethidium bromide 
(SIGMA). 
 
          Detection of Heparanase Activity  
            To determine the ability of heparanase to break down HSPGs, 35S-
labeled ECM produced by bovine corneal endothelial cells (BCECs) were 
incubated with cell lysates from various treatments. Supernatants from the 
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incubation of lysates with ECM were analyzed for degradation of 35S-labeled 
products (HS). The procedure was performed as described below. 
 
Culture of bovine corneal endothelial cells (BCECs): The primary BCECs 
were obtained from newly slaughtered cow eyes. The cow eyes were rinsed 
with 75% ethanol to sterilize the outside of the corneas. A small hole was 
made by puncturing the crystal-clear corneas with a sterilized needle. Then 
the corneas were separated from the eye by using small scissors starting 
from the small hole. After the pieces of corneas were washed thoroughly with 
CMF-DPBS, they were put onto the bottom of culture dishes with the 
endothelial side up. The BCECs were gently scraped from the cornea by 
using a metal spatula and then transferred to a 60 mm culture dish 
containing 5 ml of BCEC medium [DMEM supplemented with 10% FBS, 5% 
calf serum (CS, Life Technologies, Inc.), 50 µg/ml gentamycin, and 0.25 
µg/ml fungizone]. After these primary culture dishes were incubated at 37°C 
in a humidified incubator with a 5% CO2/ 95% air environment for 5 days, the 
media was changed and 1 ng/ml bFGF (human recombinant, SIGMA) was 
added every other day. At day ten, the primary cells were trypsinized using 
0.025% trypsin and suspended in BCEC medium, and then 2 ml of cell 
suspension were transferred into 60 mm gelatinized dishes. For gelatinizing 
dishes, a 0.2% w/v gelatin (Type B, Bovine Skin, SIGMA) solution in CMF-
DPBS was autoclaved and filtered at 0.22 µm after the solution cooled. The 
gelatin solution (3 ml) was used to cover the 60 mm culture dish which was 
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stored at 4 °C for at least 3 hrs. Cell medium was changed and bFGF was 
added every other day.   
 
Preparation of 35S-labeled extracellular matrix (ECM): Passage two to 
four of BCECs (about 2×105 cells) were seeded on 35 mm culture dishes with 
BCEC growth media supplemented by 5% dextran (SIGMA). Then 40 µCi 
Na235SO4 (540 to 590 mCi/mmol, Amersham) was added to the cultures on 
days two and five without media change, although 0.5 ml of fresh media was 
added to each dish on day five. When the cells became confluent, ten to 12 
days after seeding, cell medium was removed and the cells were washed 
three times with CMF-DPBS, and then exposed to the cell lysis solution 
(0.5% Triton X-100 and 0.025 N NH4OH in CMF-DPBS) for three to four 
minutes with gentle shaking at room temperature followed by washing three 
times with CMF-DPBS. The dishes were examined under an inverted phase 
microscope, where the extracellular matrix (ECM) appeared as a delicate 
uniform network and remained firmly attached to the plastic dishes and free 
of cellular debris and nuclei. 
 
Measurement of heparanase using 35S-labeled extracellular matrix 
(ECM): Cultured PAECs were washed twice with CMF-DPBS and 
dissociated with 0.025% trypsin, suspended in culture medium, and the cell 
numbers were counted. After washing twice with CMF-DPBS, the cells (5-
7×105) were resuspended in 1 ml phosphate buffer, pH 6.5 with 1 mM Mg+2, 
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and lysed by three cycles of freezing at -80°C and thawing at 37°C. The cell 
lysates were incubated with newly made 35S-labeled ECM for 24 hrs at 37°C. 
To evaluate the occurrence of HS degradation, 0.8 ml aliquot of the 
supernatant was applied to Sepharose 6B columns (0.9×8 cm) and gel 
filtered. Fractions of 200 µl were eluted with CMF-DPBS at a flow rate of 6 
ml/hr and counted for radioactivity by a β-scintillation counter (BECKMAN, 
LS6000IC). The high-Mr 35S-labeled material released from ECM was at 
peak I after V0 (Kav<0.2) and the degraded low-Mr 35S-labeled products was 
at peak II (0.5<Kav<0.8) according to previous studies (Matzner et al., 1985). 
Thus, intact HS should be eluted at peak I (fraction 5-10) and degraded HS 
at peak II (fraction 15-25). 
 
    4.3. Results 
          Heparanase mRNA Expression 
            To determine if heparanase mRNA is detectable in control untrated 
EC cultures, total RNA was isolated from initial confluent and non-confluent 
PAECs. Further, to determine if other cells derived from the porcine model 
produced heparanase mRNA, total RNA was isolated from untreated porcine 
tissue including porcine liver, kidney, and aortic smooth muscle. RT-PCR (10 
µl) products of each sample run on agarose gel electrophoresis, were 
negative for heparanase mRNA, as no bands appeared at 597 bp (Figure 4.1 
and Figure 4.2). 
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            To determine if heparanase mRNA is detectable in high glucose 
treated PAECs, total RNA was isolated from PAECs treated with high 
glucose. RT-PCR products, run on agarose gel, showed a positive band 
appearing at 597 bp in high glucose (30mM) treated PAECs (Figure 4.3).  To 
determine if insulin and/or heparin inhibited heparanase production induced 
by high glucose, total mRNA was isolated from control PAECs and PAECs 
treated with glucose plus insulin, glucose plus heparin and glucose plus 
insulin plus heparin. After running RT-PCR, there were no bands showing at 
597 bp (Figure 4.3). 
            To determine if free radical production and changes in osmolarity 
induce heparanase expression, total RNA was isolated from PAECs treated 
with H2O2 and with mannitol. RT-PCR products run on agarose gel 
electrophoresis showed that a positive band at 597 bp appeared in H2O2 
treated PAECs, but not in mannitol treated cells (Figure 4.4). 
            To determine if bFGF inhibits heparanase mRNA expression, total 
RNA was isolated from PAECs treated with high glucose and bFGF. RT-PCR 
products run on agarose gel electrophoresis showed that a positive band at 
597 bp in PAECs treated with 1 ng/ml or 10 ng/ml of bFGF and high glucose 
(Figure 4.5) indicating that bFGF likely does not prevent heparanase 
expression in high glucose treated cells. 
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Figure 4.1. Heparanase mRNA was not Detectable in Fresh Untreated Porcine 
Tissue 
 
Samples of liver, kidney and aortic smooth muscle were obtained from fresh porcine 
tissue. Each sample (50 mg) was stored in RNA stabilization reagent at room 
temperature for three or four days and then total tissue RNA was extracted. Lane 1: 
DNA ladder, Lane 2: porcine liver, Lane 3: porcine kidney, Lane 4: glucose treated 
PAECs used as positive control, Lane 5: porcine aortic smooth muscle. 
 
Total RNA was isolated from PAECs and fresh porcine liver, kidney and aortic 
smooth muscle with RNeasy extraction Kit from QIAGEN. Total RNA (1µg) was 
run on agarose gel (1.5% containing 0.5-1 µg/ml ethidium bromide). β-actin mRNA 
expression was used as an internal control. Heparanase mRNA was expressed as a 
597 bp cDNA close to 600 bp in the DNA ladder. 
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Figure 4.2. Heparanase mRNA was not Detectable in Primary Non-confluent 
and Confluent PAECs 
 
Primary non-confluent (day 8) and confluent (day 15) cultured PAECs were used. 
Confluent primary PAECs treated with high glucose (30mM) for seven days, and 
then total RNA was extracted. Lane 1: DNA ladder, Lane 2: primary non-confluent, 
Lane 3: primary confluent treated with high glucose, Lane 4: primary confluent, 
Lane 5: high glucose treated passage 4 PAECs used as a positive control. 
 
Total RNA was isolated from non-confluent and confluent PAECs with RNeasy 
extraction Kit from QIAGEN. Total RNA (1µg) was run on agarose gel (1.5% 
containing 0.5-1 µg/ml ethidium bromide). β-actin mRNA expression was used as an 
internal control. Heparanase mRNA was expressed as a 597 bp cDNA close to 600 
bp in the DNA ladder. 
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Figure 4.3. High Glucose Induced Heparanase mRNA which was Inhibited by 
Insulin and/or Heparin 
 
Confluent (passage 4) PAECs were treated as follows: Lane 2: control, Lane 3: high 
glucose (30 mM), Lane 4: high glucose plus heparin (0.5 µg/ml), Lane 5: high 
glucose plus insulin (1 U/ml), Lane 6: high glucose plus heparin plus insulin for 
seven days. Medium was changed and reagents were added fresh every other day. 
Total RNA was extracted 48 hours after the last addition of reagents. Lane 1: DNA 
ladder. 
 
Total RNA was isolated from PAECs treated high glucose and/or heparin and/or 
insulin and control cells with RNeasy extraction Kit from QIAGEN. Total RNA 
(1µg) was run on agarose gel (1.5% containing 0.5-1 µg/ml ethidium bromide). β-
actin mRNA expression was used as an internal control. Heparanase mRNA was 
expressed as a 597 bp cDNA close to 600 bp in the DNA ladder. 
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Figure 4.4. Heparanase mRNA was Induced by H2O2, but not Mannitol 
 
Confluent PAECs (passage 4) were treated with mannitol (30 mM) for seven days. 
Medium was changed and fresh mannitol added every other day. Total RNA was 
extracted 48 hours after last mannitol addition. Confluent PAECs (passage 4) were 
treated with H2O2 (0.1 mM) for 24 hours and then total RNA was extracted. Lane 1: 
DNA ladder, Lane 2: mannitol, Lane 3: H2O2, Lane 4: high glucose as a positive 
control. 
 
Total RNA was isolated from PAECs treated with H2O2 or mannitol with RNeasy 
extraction Kit from QIAGEN. Total RNA (1µg) was run on agarose gel (1.5% 
containing 0.5-1 µg/ml ethidium bromide). β-actin mRNA expression was used as an 
internal control. Heparanase mRNA was expressed as a 597 bp cDNA close to 600 
bp in the DNA ladder. 
 
 
 
 
 
 
 
 
1           2          3           4
600 bp
β-actin
 92
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Heparanase mRNA was Expressed in High Glucose and bFGF 
Treated PAECs 
 
Confluent PAECs (passage 4) were treated with high glucose (30 mM) and bFGF (1 
ng/ml and 10 ng/ml) for seven days. Medium was changed and fresh glucose and 
bFGF added every other day. Total RNA was extracted 48 hours after last addition of 
glucose and bFGF. Lane 1: DNA ladder, Lane 2: control, Lane 3: glucose plus bFGF 
(1 ng/ml), Lane 4: glucose plus bFGF (10 ng/ml). 
 
Total RNA was isolated from PAECs treated with high glucose and bFGF with 
RNeasy extraction Kit from QIAGEN. Total RNA (1µg) was run on agarose gel 
(1.5% containing 0.5-1 µg/ml ethidium bromide). β-actin mRNA expression was 
used as an internal control. Heparanase mRNA was expressed as a 597 bp cDNA 
close to 600 bp in the DNA ladder. 
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       Heparanase Activity Assay 
           In Figure 4.6 and 4.7 are shown recovery of intact HS degaded HS 
following treatment of ECM with lysates of ECs exposed to various 
treatments. Incubation of 35S-labeled ECM with high glucose or H2O2 treated 
PAEC lysates resulted in release of low-Mr 35S-labeled degradation products 
into the incubation medium at peak II (0.5<Kav<0.8, fraction 15-25). Results 
were similar when the ECM was treated with 0.1 U/ml heparinase I in 
phosphate buffer (positive control) shown in Figure 4.7. Addition of PAECs 
lysates from cells treated with insulin and/or heparin as well as high glucose 
to the ECM did not show the release of low-Mr degradation products, but 
showed high-Mr 35S-labeled products at peak I (Kav<0.2, fraction 5-10) 
shown in Figure 4.6. Lysates from mannitol treated PAECs showed high-Mr 
35S-labeled products at peak I with no degradation products found at peak II 
shown in Figure 4.7. Cell lysates in DPBS from control untreated PAECs 
showed no HS degradation products at peak I (negative control) shown in 
Figure 4.7. 
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Figure 4.6. High Glucose Induced Heparanase Activity which was Inhibited by 
Insulin and/or Heparin 
 
Heparanase activity was expressed in high glucose (30 mM) treated PAECs (●) 
shown at peak II, but not in high glucose +heparin (0.5 µg/ml) (▼), high glucose 
+insulin (1U/ml) (○), and high glucose + heparin + insulin (∆) treated cells, shown at 
peak I. (V0: void volum, Vt: total volum) 
 
35S-labeled ECM was produced by incubating bovine corneal endothelial cells 
(passage two to four) in 35 mm culture dishes with Na235SO4 (80 µCi/ml). Confluent 
cells were removed with a lystic solution (0.5% Triton X-100 and 0.025 N NH4OH 
in CMF-DPBS), leaving the ECM firmly attached to the dishes. 
 
PAECs (passage 4) were treated with high glucose and heparin and/or insulin for 
seven days or H2O2 for 24 hrs. Cells were lysed by three cycles of freezing at -80ºC 
and thawing at 37 ºC in pH 6.5 phosphate buffer with 1 mM Mg2+. PAECs lysate (1 
ml) was incubated with 35S-labeled ECM at 37ºC for 24 hrs. The incubation 
supernatant (0.8 ml) was gel filtered in Sepharose 6B columns. Fractions (200 µl) 
were eluted with CMF-DPBS at a flow rate of 6 ml/hr and radioactivity by a β-
scintillation counter. Heparanase activity was detected by elution of degraded HS at 
peak II. Non-degraded HS eluted at peak I showed no heparanase activity. 
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Figure 4.7. Heparanase Activity was Present in H2O2 but not in Mannitol 
Treated PAECs.  
 
ECM incubated with heparinase I (0.1 U/ml) (positive control) (●) and CMF-DPBS 
(negative contol) (▼) are showed at peak II and at peak I respectively. Heparanase 
activity was expressed in H2O2 (0.1 mM) treated PAECs (■) shown at peak II, but 
not in mannitol (30 mM) preated PAECs (♦), shown at peak I. (V0: void volum, Vt: 
total volum) 
 
 
35S-labeled ECM was produced by incubating bovine corneal endothelial cells 
(passage two to four) in 35 mm culture dishes with Na235SO4 (80 µCi/ml). Confluent 
cells were removed with a lystic solution (0.5% Triton X-100 and 0.025 N NH4OH 
in CMF-DPBS), leaving the ECM firmly attached to the dishes. 
  
PAECs (passage 4) were treated with mannitol for seven days or H2O2 for 24 hrs. 
Cells were lysed by three cycles of freezing at -80ºC and thawing at 37ºC in pH 6.5 
phosphate buffer with 1 mM Mg2+. PAECs lysate (1 ml) was incubated with 35S-
labeled ECM at 37ºC for 24 hrs. The incubation supernatant (0.8 ml) was gel filtered 
in Sepharose 6B columns. Fractions (200 µl) were eluted with CMF-DPBS at a flow 
rate of 6 ml/hr and radioactivity by a β-scintillation counter. Heparanase activity was 
detected by elution of degraded HS at peak II. Non-degraded HS eluted at peak I 
showed no heparanase activity. 
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    4.4. Discussion 
            The monolayer of endothelial cells (ECs) are the major metabolically 
active cells lining all blood and lymphatic vessels and play an important role 
in the structural integrity and normal function in the circulatory system. 
Heparan sulfate proteoglycans (HSPGs) are synthesized by vascular ECs 
and incorporated into their surface, ECM and basement membrane. The 
HSPG macromolecules consist of a protein core to which several 
polysaccharide chains called GAGs are covalently attached (Muir, 1977). 
The GAGs are highly negatively charged due to sulfate and carboxylate 
residues present in their structure (Bernfield et al., 1999). The negative 
charges on the luminal surface of the vascular vessel wall are thought to play 
a major role in controlling vascular permeability by acting as a charge 
barrier to the transvascular movement of the largely anionic plasma proteins 
such as albumin (Hardebo and Kahlstrom, 1985). Previous studies have 
shown that HS specifically interacts with various adhesive macromolecules 
such as fibronectin, laminin and collagen, and hence its degradation may 
disassemble the ECM and basement membrane, resulting in EC detachment 
and damage to vessel wall integrity (Kraemer, 1971). 
            Heparanase is an endo-β-D-glucuronidase that breaks down the 
GAG chains of HSPG at specific sites, and can act on the endothelial cell 
surface, ECM and basement membrane. Some human and animal 
heparanase genes were recently cloned and heparanase proteins were 
encoded by the genes, however, the porcine heparanase gene and protein 
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has not been previously studied. Alignment of the human, mouse and rat 
heparanase amino acid sequences corresponding to the 50-KDa human 
mature enzyme reveal 80-93% identity (Vlodavsky et al., 1999; Hulett et al., 
1999). Therefore, the rat heparanase gene was selected to design the 
primers to amplify the heparanase cDNA for porcine tissue and PAECs in our 
studies. There was no heparanase mRNA expression in fresh untreated 
porcine tissue and initial primary confluent and non-confluent PAEC cultures 
(Figure 4.1 and Figure 4.2). This is similar to what has been demonstrated in 
humans (Godder et al., 1991). Thus, the PAECs can be used as an in vitro 
model to study heparanase expression in ECs for human disease. 
            It was reported that heparanase is rarely found in intact original 
human ECs and their lysates or in bovine aortic ECs following exposure to 
various physiological activators such as bFGF, thrombin, endotoxin, 
interleukin-1 (Il-1), TNF, calcium ionophore, or radiation (Godder et al., 1991; 
Nakajima et al., 1986). This finding suggests that ECs contain a heparanase 
that is released only from injured ECs that may then degrade HSPG.  HSPG 
degradation involves vessel wall disruption and new vessel formation both in 
normal and pathological situations such as wound healing, tissue repair and 
cancer progression (Moscatelli et al., 1985; 1986). Our present study is the 
first to show that heparanase mRNA expression is found in PAECs treated 
with high glucose and H2O2 (Figure 4.3 and Figure 4.4). PAECs injury was 
further demonstrated by a decrease in numbers of live cell /culture and 
increase in lactate dehydrogenase (LDH) release in cell medium in high 
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glucose treated cells compared to control cells (Mandal et al., 2002). 
Heparanase activity was found in PAECs treated with high glucose and H2O2 
(Figure 4.5 and Figure 4.6) in agreement with the finding of heparanase 
mRNA expressed in PAECs treated with high glucose and H2O2.  
Heparanase expression and degradation of HS in high glucose treated 
PAECs are likely to contribute to EC injury. An increase in osmolarity is likely 
not the cause of high glucose injury and heparanase upregulation since no 
expression of heparanase mRNA and protein was found in mannitol treated 
cells (Figure 4.4 and Figure 4.6). Heparanase expressed in H2O2 treated 
cells indicates that the production of free radicals may be one of the 
mechanisms in the pathway by which hyperglycemia induces endothelial 
injury and upregulation of heparanase. Previous studies found decreased 
serum HS and increased urine GAGs in patients with overt diabetic 
nephropathy (Yokoyama et al., 1999, Perez-Blanco et al., 2000), and less 
GAG content in glomerular basement membrane of the patients with diabetic 
nephropathy compared to nondiabetic control subjects (Parthasarathy and 
Spiro, 1982). In patients with diabetic nephropathy, the decreased HSPG in 
the glomerular basement membrane correlated with the degree of proteinuria 
(Tamsma et al., 1994). As well, changes in content and structure of HSPG in 
the glomerular basement membrane were thought to be associated with 
proteinuria in patients with diabetic nephropathy (Rosenzweig and Kanwar, 
1982). Increased glomerular permeability to largely anionic plasma proteins 
may result from loss of HSPG, the negative charge barrier (Kanwar et al., 
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1980) due to HS degradation by heparanase. Heparanase activity was 
shown in renal glomerular cells and in the urine of diabetic patients (Katz et 
al., 2002). In addition, a decrease in HS content in the aortic intima of 
diabetic patients has been observed (Wasty et al., 1993), suggesting that the 
abnormalities in HS metabolism could occur in the whole cardiovascular 
system and not only in the kidney, indicating association between 
cardiovascular complications and nephropathy. However, it is still unknown 
where heparanase is produced in the vasculature. 
            The capillary ECs, injured by high glucose in the glomerulus, may 
induce heparanase upregulation. Heparanase expressed in ECs in both large 
and small vessels may play an important role in EC dysfunction. ECs in 
macro and micro vessels have different properties, but both are 
characterized by the same pathological features in diabetes mellitus. In both 
macro and micro vessels, exaggerated proliferation of ECs and thickening of 
the basement membrane result in narrowing of the vessel lumen which 
contributes to premature thrombosis, and ischemia (Perejda et al., 1987, 
Richardson et al., 1980; Colwell and Lopes-Virella, 1988). Heparanase 
upregulation in injured ECs could be a common factor for pathological effects 
presented in both endothelial cells from both large and small vessels. 
            Heparin is intracellularly located in the mast cells and released as a 
GAG. Like HS, heparin controls vascular permeability by forming a negative 
charge barrier on the luminal surface of endothelium (Muir, 1977). In 
addition, exogenous heparin is used as an anticoagulant agent and 
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ameliorates increased vascular permeability caused by various polycationic 
substances (Fairman et al., 1987; Peterson et al., 1987). The ability of 
heparin to protect endothelium has been shown in several studies. Heparin 
accumulates in endothelium against a concentration gradient (Hiebert et al., 
1993). Heparin treatment results in increased formation of HS in cultured EC 
surfaces (Nader et al., 1991) and protects cultured ECs from injury when 
exposed to free radicals (Hiebert and Liu, 1990). Our studies support the 
idea that heparin is protective and prevents the upregulation of heparanase 
in high glucose injured endothelium. Insulin regulates glucose metabolism 
and promotes glucose up-take and utilization to reduce the glucose 
concentration in hyperglycemia. Heparin, insulin and a combination of insulin 
and heparin prevent the intercellular gaps in ECs exposed to high glucose 
(Mandal et al., 2000). Similar results obtained from our experiment showed 
an increase in live cell number and decreased LDH release in PAECs treated 
with high glucose plus insulin and/or heparin compared to high glucose alone 
(Mandal et al., 2002). Our results in the present study, show no expression of 
heparanase mRNA and activity in high glucose plus insulin and/or heparin 
treated cells, agreeing with the protective effects demonstrated in previous 
studies, and also support the idea that GAGs and heparin-like polyanionic 
molecules inhibit heparanase upregulation (Bar-Ner et al., 1987). This study 
further demonstrates, at the gene level, inhibition of EC heparanase 
expression in high glucose treated cells by insulin and/or heparin, but not 
bFGF, even though bFGF has the ability to enhance cell proliferation.  
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            In summary, diabetic vascular complications are primarily caused by 
endothelial injury. Degradation of HSPGs contributes to endothelial cell injury 
resulting in loss of anionic charges in the vasculature and increasing vascular 
permeability as well as other pathological effects. Our studies confirm that 
heparanase over-expression is associated with endothelial injury and could 
contribute to the diabetic vascular complications. Furthermore, insulin and 
heparin, alone or in combination, protect ECs from injury through down-
regulation of heparanase expression induced by high glucose. These results 
provide the theoretical background for further studies in the field of 
pharmacological intervention in diabetic vascular disease. 
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5. GENERAL DISCUSSION 
 
            Endothelial dysfunction induced by hyperglycemia is believed to be a 
pivotal stage in diabetic cardiovascular complications which is the main 
causes of morbidity and mortality in diabetes mellitus. A considerable body of 
evidence has shown that many metabolic abnormalities and by-products are 
involved in the pathways of endothelial dysfunction. In the present study, in 
order to mimic hyperglycaemia cultured aortic endothelial cells (ECs) were 
treated with high concentrations of glucose (30 mM). Treatment of cells with 
high glucose cause damage to ECs shown by a decrease in live cell number 
and increase in LDH release which is in agreement with previous evidence 
(Lorenzi, 1992). When Heparinase I was added to ECs cultured in serum free 
medium, EC damage was similar to that seen in high glucose treatment. 
These data suggest upregulation of heparanase in the diabetic condition may 
play a role in endothelial dysfunction. However, it is likely that EC injury 
caused by high glucose is more complicated than heparanase upregulation 
alone and many mechanisms in addition to heparanase induction are likely 
involved when ECs are injured by high glucose. Heparanase mRNA and 
activity, expressed in cells treated with high glucose, indicate that high 
glucose indeed induces heparanase over-expression and heparanase is an 
additional contributing factor in cells injured by high glucose. Katz et al., 
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(2002) identified that heparanase activity was found in both the glomerular 
mesangial and epithelial cells and in the urine of diabetic patients. As of now 
there have been no studies relating high glucose to upregulation of 
heparanase in endothelial cells. Heparanase is rarely expressed in intact 
original ECs and their lysates shown in studies with human and animal cells 
exposed to physiological stimuli (Godder et al., 1991). Our present studies 
showed that heparanase mRNA was not expressed in primary cultured 
control and passage 4 control porcine aortic ECs further confirming the 
above results. In addition we observed that heparanase mRNA was not 
expressed in fresh untreated porcine tissue such as liver, kidney, and aortic 
smooth muscle. Since heparanase is not normally expressed in human 
tissue, porcine ECs can be safely used as an in vitro model to study 
heparanase expression for human vascular diseases. Our studies are the 
first to show that heparanase mRNA and activity were expressed in ECs 
treated with high glucose suggesting EC injury in hyperglycemia, caused by 
upregulation of heparanase, contributes to diabetic vascular complications. 
            Since heparanase over-expression in ECs under hyperglycemic 
conditions is demonstrated in our study, the degradation of HSPG is likely 
involved in EC injury in diabetic vascular complications. Heparanase breaks 
down HSPG on the cell surface and in the ECM resulting in the release of 
enzymes, plasma proteins and growth factors such as bFGF and causing EC 
damage and vessel wall destruction and dysfunction. Loss of bFGF affects 
DNA synthesis and the processes of cell proliferation, replication and 
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differentiation. HSPG can act both as reservoirs of growth, differentiation and 
migration of many cell types (Folkman and Klagsbru, 1987). It is known that 
bFGF exerts its function only in the presence of HS through the formation of 
a bFGF/HS/bFGFR complex. Studies with cultured cells, deficient in cell 
surface HS, showed that the cells failed to proliferate in the presence of HS 
dependent growth factors even at significantly high concentrations of these 
growth factors. (Walker et al., 1994; Fannon and Nugent, 1996). Our results 
showed that bFGF alone could not protect cells from high glucose or 
heparinase I injury, but bFGF and heparin could protect cells from 
heparinase I injury in agreement with these findings. In addition, the result of 
heparanase mRNA expression in bFGF and high glucose treated ECs 
indicates that bFGF alone (even at doses as high as 10 ng/ml) could not 
inhibit the upregulation of heparanase induced by high glucose, further 
confirming the above findings. In the presence of heparin, bFGF protected 
cells from high glucose or heparinase I injury showed by increased live cell 
number and decreased LDH release as well as prevention of the expression 
of heparanase mRNA and activity compared to high glucose alone treated 
ECs. This suggests that heparin has the ability to ensure the physiological 
function of bFGF by inhibiting heparanase production either through 
promoting HS synthesis or reducing the degradation of HS. This result is also 
consistant with the idea that GAGs and heparin-like polyanionic molecules 
inhibit heparanase upregulation (Bar-Ner et al., 1987). 
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            As we know, insulin is capable to enhancing cell proliferation by 
acting as a growth factor which is also demonstrated in our study on ECs 
treated with insulin alone. Addition of insulin to cell medium protected ECs 
from high glucose or heparinase I injury directly shown by a significantly 
increased live cell number and decreased LDH release compared to high 
glucose or heparinase I treatment alone. The combination of insulin and 
heparin protected ECs injured by high glucose or heparinase I even further 
shown by the highest live cell number and significantly decreased LDH 
release in each experiment. Insulin alone or in combination with heparin 
inhibited the up-regulation of heparanase demonstrated by the lack of 
heparanase mRNA and activity expressed in cells treated with high glucose 
and insulin and/or heparin. These findings agree with the observation that 
insulin and/or heparin prevented the intercellular gaps of ECs exposed to 
high glucose (Mandal et al., 2000). In the presence of bFGF, insulin and 
heparin also possessed the same protective effects on ECs injured by high 
glucose or heparinase I.  
            However, the exact mechanisms underlying insulins protective effect 
on ECs injured by hyperglycemia are poorly understood. It has been shown 
that insulin-stimulated glucose uptake and insulin-stimulated endothelial 
function are regulated by similar signalling pathways (Rask-Madsen et al., 
2001; Krook et al., 1997). The endothelial derived NO could play a role in 
these common insulin pathways as insulin can increase both cell proliferation 
and NO production in cultured ECs. NO is able to protect the vasculature 
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from dysfunction through its ability to regulate vascular tone and blood 
pressure and to reduce the production of reactive oxygen species (ROS) 
(Shen et al., 1994). Increased ROS, such as H2O2, may contribute to 
heparanase upregulation caused by high glucose. Our results showing 
heparanase mRNA and activity expressed in cells treated with H2O2 
indicates that the production of ROS in hyperglycemia may induce the 
expression of heparanase. Previous studies show high glucose-derived 
induction of oxidative stress in human endothelial cells and porcine aortic 
vascular smooth muscle cells (Ceriello et al., 1992; Sharpe et al., 1998). It is 
plausible that the induction of heparanase by hyperglycemia is mediated by 
the production of ROS. Our results showing that heparanase induction by 
high glucose was inhibited by insulin, demonstrated by no heparanase 
mRNA and activity expressed in high glucose and insulin treated cells, 
suggest that increased NO production by insulin may suppress 
hyperglycemic oxidative stress, and thus inhibit heparanase upregulation. 
Since heparin also has the ability to protect cells from oxidative damage, the 
combination of insulin and heparin protecting cells from heparanase injury 
induced by high glucose could represent the common mechanism linking 
heparin and insulin in the same pathway related to the amelioration of 
oxidative stress and inhibition of heparanase upregulation.  
            In addition, an increase in osmolarity is likely not the cause of ECs 
injured by high glucose since heparanase mRNA and activity was not 
expressed in mannitol treated cells in the present study and no decrease in 
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cell proliferation and increase in cell apoptosis was shown by mannitol 
treatment in other studies (Ortiz et al., 1997). 
            In conclusion, our results from both cellular and molecular studies 
demonstrated that hyperglycemia is a critical factor contributing to endothelial 
injury which is in agreement with previous studies. For the first time we have 
determined that heparanase is induced by hyperglycemia and likely 
degrades HSPG suggesting this fundamental mechanism of EC injury in 
diabetic vascular complications. Even though the pathways or mechanisms 
involved in the protection on EC injury by insulin and/or heparin and/or bFGF 
may be quite variable, the combination of two or of three compounds exerts 
synergistically protective effects on EC injury under high glucose conditions. 
These results may shed some light on the mechanisms involved and on 
innovation of therapeutic drugs for human diseases associated with 
heparanase production such as diabetes mellitus and cancer. 
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6. CONCLUSION 
 
• Porcine aortic endothelial cells can be used as an in vitro model to 
study heparanase expression as heparanase mRNA was not shown in 
control primary cultured confluent and non-confluent PAECs or in 
fresh untreated porcine tissue such as liver, kidney and aortic smooth 
muscle. 
 
• Hyperglycemia is a cause of endothelial cell injury as live cell number 
decreased and LDH release increased in cells treated with high 
glucose concentrations which mimic hyperglycemia. 
 
• Heparanase induction represents a mechanism of endothelial injury in 
hyperglycemia as heparanase mRNA and activity was expressed in 
ECs treated with high glucose. Also heparinase I damaged cultured 
ECs in serum free conditions. 
 
• The production of reactive oxygen species may be involved in the 
mechanism of heparanase upregulation since heparanase mRNA and 
activity was expressed in ECs treated with H2O2. 
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• Cells injury in high glucose treated cultures was not due to changes in 
osmolarity since heparanase mRNA and activity was not expressed in 
ECs treated with equally high concentrations of mannitol. 
 
• Insulin and heparin alone or in combination protect cells from high 
glucose or heparinase I injury and inhibit heparanase mRNA 
expression and activity. 
 
• bFGF alone cannot protect cells from high glucose or heparinase I 
injury and cannot inhibit heparanase mRNA expression. 
 
• The combination of heparin, insulin and bFGF can protect cells from 
high glucose and heparinase I injury. 
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